Document:

Exhibit
10.2

 

PRODUCT
PLACEMENT MEMBERSHIP AGREEMENT

 

This
Product Placement Membership Agreement (“Agreement”), dated as of July 10th, 2020 (the “Effective
Date”), is entered into by and between TAURIGA SCIENCES, INC. a Florida corporation (“Client”), and
KushCo Holdings, Inc., a Nevada corporation (“Placement Agent”), collectively referred to as the “Parties”
and each a “Party” and is based upon the following facts and circumstances:

 

WHEREAS,
Client is in the business of manufacturing and distributing certain legally compliant hemp derived products (the “Products”);

 

WHEREAS,
Placement Agent is in the business of providing certain services, including without limitation, retail activation, product
incubation, branding and marketing solutions, and sales management of certain products (the “Services”),
and NOW, THEREFORE, in consideration of the mutual covenants herein contained, Client and Placement Agent hereby agree as
follows:

 

1.
Defined Terms. In addition to other terms defined elsewhere in this Agreement, the following terms shall have the following
meanings:

 

1.1
“Affiliate” shall mean, any individual, corporation, company, partnership, joint venture, unincorporated organization
or other entity directly or indirectly controlling, controlled by or under common control with the applicable Party.

 

1.2
“Transaction(s)” shall mean any sale, exchange, transfer, conveyance, option to purchase the Products or other
products sold and distributed by the Client to a third-party or third-parties utilizing any of the Service(s) provided by Placement
Agent.

 

2.
Fees. If Client or any Affiliate of Client consummates any Transaction(s) with a third-party for the Product(s), Placement
Agent shall be paid a fee equal to ten and 00/100 percent (10.00%) of the total gross sales for such Transaction(s) for any and
all Products or other products sold and distributed by Client to a third-party or third-parties utilizing any of the Service(s)
provided by Placement Agent (each the “Placement Fee” and collectively, the “Placement Fees”).
The Placement Fee shall be earned as of the date of the respective Transaction and shall be paid in cash by Client to Placement
Agent on a monthly basis and no later than the last calendar day of each calendar month.

 

3.
Monthly Reporting & Audit. Client shall provide Placement Agent monthly sales statements illustrating the number of
Transaction(s) completed during each calendar month, and such other information relating to this Agreement as may be reasonably
requested by the Placement Agent. Client shall provide Placement Agent with a monthly rolling forecast of estimated Transaction(s)
for the following month. The forecast is for planning purposes only and is not binding. Placement Agent will have the right, upon
reasonable request, to audit and review the books and records of Client sufficient to review and confirm the Placement Fee(s).
Any such audit will be conducted at Placement Agent’s expense and at such times and in such a manner as to not unreasonably
interfere with Client’s normal operations. Client shall maintain all such books and records for a period of three (3) years
after the closing of any Transaction(s).

 

    	Page 1 of 9

     

    

 

4.
Placement Agent’s Role. Client hereby acknowledges and agrees that (a) Placement Agent may find, procure and introduce
Client to certain entities or persons or their Affiliate(s) that Placement Agent has identified that may be willing to entering
into the Transaction with Client, (b) Client has at all times been (or will be) represented by legal counsel of its own choice;
and (c) nothing in this Agreement shall restrict Placement Agent from providing the same or similar services to other parties.

 

5.
Term; Termination & Recognition. The term of this Agreement commences on the Effective Date and continues for a period
of two (2) years, unless earlier terminated as provided under this Agreement. Placement Agent may terminate this Agreement upon
sixty (60) days’ prior written notice to the Client. Termination or expiration of this Agreement for any reason will not
negate any obligation of the Client, which arose prior to the effective date of such termination, including without limitation
Client’s obligation to compensate Placement Agent in accordance with the payment terms agreed upon for all Services performed
prior to termination or expiration. Notwithstanding anything to the contrary, if within two (2) years after the expiration or
earlier termination of this this Agreement a Transaction is completed, then Client shall pay Placement Agent the Placement Fee
in accordance with the provisions of this Agreement on account of such Transaction(s).

 

6.
Notices. Any notices or other communications between Client and Placement Agent may be given at the addresses set forth
below:

 

	 	To
    Placement Agent:	KushCo
    Holdings, Inc.,
	 	 	6261
    Katella Ave., Suite 250
	 	 	Cypress,
    CA 90630
	 	 	Attn:
    Legal@Kushco.com
	 	 	 
	 	To
    Client:	Tauriga
    Sciences, Inc.
	 	 	555
    Madison Avenue, 5th Foor
	 	 	New
    York, NY 10022
	 	 	Attn:
    Seth M. Shaw
	 	 	Email:
    sshaw@tauriga.com
	 	 	Tel.
    (917) 796 9926

 

Any
notice or communication under this Agreement must be in writing and sent via personal delivery, overnight courier service, email,
or certified or registered mail, postage prepaid, return receipt requested and addressed to the to the address stated above or
to another address as that Party may subsequently designate by notice and shall be deemed given on the date of delivery. Any such
notice shall be deemed delivered and given as of the date so delivered, if delivered personally, the following business day if
delivered by overnight courtier or email, or seventy-two (72) hours after deposit in a regularly maintained receptacle for the
deposit of United States mail, postage paid, addressed and sent as aforesaid.

 

    	Page 2 of 9

     

    

 

7.
Liability for Due Diligence Costs. All reasonable out-of-pocket costs incurred by the Client hereto and/or their respective
affiliates in connection with the Transaction(s) (including, without limitation, due diligence expenses, legal fees, costs of
travel, costs of third party reports, preparation and negotiation of this Agreement and the documents necessary to consummate
the Transaction(s), formation of entities intended to be used in connection with the Transaction(s), transfer taxes, conveyance
taxes, intangible taxes and other similar taxes, escrow fees, Placement Fees and any other expenses of any kind or nature incurred
in connection with the Transaction(s) will be paid by Client. To the extent that any such costs are incurred by Placement Agent
on behalf of Client, Placement Agent shall promptly reimburse Placement Agent for the cost thereof.

 

8.
Late Fees. In the event Client fails to make any payments when due under this Agreement then Client will be charged a late
fee of five percent (5%) of the outstanding balance per month or the maximum rate allowed by applicable law, whichever is lower.
Placement Agent shall recover any out-of-pocket expenses incurred in collecting payments due, including, without limitation, any
bank charges for returned checks and attorneys’ fees. In the event of any late payment by Client that is not cured within
five (5) days from the date of notice thereof, Placement Agent may decline to offer any additional Service(s) until all amounts
due and late fees are paid in full, without in any way affecting its rights under this Agreement. Placement Agent may enforce
the foregoing rights without waiving any and all other rights or remedies it may have for any breach of this Agreement.

 

9.
Independent Contractor Status. Client and Placement Agent acknowledge and declare that neither Party intends to create
an employee/employer relationship, nor an agent/principal relationship, by this Agreement. It is the Parties intention that the
Placement Agent shall have an independent contractor status and not be an employee for any purposes including, but not limited
to, the application of the Federal Insurance Contribution Act, Social Security Act, Federal Unemployment Tax Act, provisions of
the Internal Revenue Code, State Revenue and Taxation Code relating to income tax withholding at the source of income, Workers’
Compensation Insurance Code 401(k) and other benefit payments and third party liability claims. Placement Agent will retain sole
and absolute discretion in the manner and means of carrying out their activities and responsibilities under this Agreement. This
Agreement will not be considered or construed to be a partnership or joint venture and neither party shall not be liable for any
obligations incurred by the other unless specifically authorized in writing by the both Parties.

 

10.
Insurance. During the term of this Agreement, Client shall, at its own expense, maintain and carry insurance in full force
and effect which includes, but is not limited to, commercial general liability in a sum reasonably appropriate for Client’s
industry and size with financially sound and reputable insurers. Upon Placement Agent’s request, Client shall provide Placement
Agent with a certificate of insurance from Client’s insurer evidencing the insurance coverage specified in this Agreement.
Client shall provide Placement Agent with thirty (30) days’ advance written notice in the event of a cancellation or material
change in Client’s insurance policy.

 

    	Page 3 of 9

     

    

 

11. Disclaimer
of Warranties; Limitation of Liability. Placement Agent makes no warranties, whether written, oral, or implied. Placement
Agent expressly disclaims the making of, and Client acknowledges that it has not received, any warranty or guarantee, express
or implied or statutory, as to the past, present or future performance of the Services or the potential performance or
success of a Transaction. Furthermore, Client acknowledges that Placement Agent is not obligated to independently verify the
accuracy or the completeness of the information provided to Placement Agent and/or any party entering into a Transaction with
Client, and that Placement Agent is not responsible for any inaccurate or incomplete data provided by such parties. In no
event shall the Placement Agent be liable, whether in contract or tort (including negligence or product liability), for any
of the following arising out of or concerning this Agreement, however caused: consequential, special, moral, incidental,
indirect, reliance, punitive or exemplary damages, loss of goodwill, profits, use, opportunities, revenue or savings;
business interruption; or loss; regardless of (a) whether such damages were foreseeable, (b) whether the Placement Agent was
advised of the possibility of such damages, (c) the legal or equitable theory (contract, tort or otherwise) upon which the
claim is based, and (d) the failure of any agreed or other remedy of its essential purpose. In no event shall the Placement
Agent’s aggregate liability arising out of or related to this Agreement or its subject matter, for breach of contract,
tort (including negligence or product liability) or otherwise, exceed the total amounts paid to the Placement Agent by Client
for the Services sold hereunder.

 

12. Indemnity.
Client hereby assumes all liability for, and shall defend (if required by Placement Agent and with counsel acceptable to
Placement Agent), indemnify, defend, and hold Placement Agent and its affiliated companies, and their directors, officers,
employees, shareholders, agents, affiliates, successors and assigns, harmless from and against any and all liabilities,
claims, demands, suits, actions, proceedings, judgments, losses, damages, penalties, fines or other sanctions, costs or
expenses of any nature whatsoever (including, without limitation, attorneys’ fees and expenses through all appeals),
whether arising directly or indirectly or whether in contract, tort (including negligence), strict liability, product
liability or otherwise, arising from or out of: (i) Client’s acts or omissions under this Agreement, including but not
limited to claims of product liability; (ii) the manufacture, delivery, or other disposition, provisioning, or supply of any
Product, if the claim is a result of Client’s actions or non-actions; (iii) product recalls related to manufacturing,
delivery, or other disposition or safety of any Products or other products distributed by or through the Client, whether or
not initiated by Client; (iv) any breach of representation, warranty, covenant or agreement on the part of Client under this
Agreement; (v) any other failure of Client to comply with its obligations hereunder; or (vi) any failure or alleged failure
to comply with applicable federal or state laws or regulations (including those promulgated by the USDA, FDA, FTC and state
agencies). The provisions of this section shall survive the expiration or termination of this Agreement. The Placement Agent
shall notify Client promptly of any such suit, claim or proceeding and give Client authority, information, and reasonable
assistance (at Client’s sole expense) for the defense of same, and Client shall pay all damages and costs awarded
therein. If the Placement Agent is necessarily joined in a legal action, the Placement Agent may elect to be represented by
Client’s selected legal counsel, provided that Client’s pays all legal fees (including attorneys’ fees) and
expenses of the Placement Agent. Notwithstanding the foregoing, any settlement of such suit, claim or proceeding shall be
subject to the Placement Agent’s consent, such consent not to be unreasonably withheld.

 

13.
Publication. Placement Agent shall have the right to post, share, list or otherwise use, including, without limitation,
in connection with the Placement Agent’s website, social media, print and marketing materials (collectively, “Use”)
that Client is a member and/or customer of Placement Agent.

 

    	Page 4 of 9

     

    

 

14.
Compliance with Laws. The Parties shall comply with all rules, orders, determinations, laws and ordinances of any federal,
state or local authority having or exercising jurisdiction over Transaction or the subject matter of this Agreement, including,
without limitation, laws proscribing discrimination in the sale of real property. Client is responsible for compliance with all
licensing requirements necessary in connection with any and all Transaction(s). Client will comply with all applicable laws with
regard to the manufacturing, production and sale of any Product(s) pursuant this Agreement, and will obtain, at its sole cost
and expense, all necessary registrations, approvals, permits, and other authorizations needed, whether from regulatory authorities
or otherwise, in connection with such activities. Client will not engage in any illegal or unethical practices in connection with
the Service(s) offered hereunder. Client shall comply with all applicable laws, regulations and ordinances, including compliance
and cooperation with IRS Form 8300, Report of Cash Payments Over $10,000 received in a trade or business.

 

15.
Governing Law. The laws of the State of California shall govern the legality, validity and enforceability of this Agreement,
the construction of its terms, conditions and covenants, and the interpretation of the rights and duties of Client and Placement
Agent.

 

16.
Waiver of Jury Trial; Attorney’s Fees. Each Party hereto hereby acknowledges and agrees that any controversy that
may arise under this agreement is likely to involve complicated and difficult issues and, therefore, each such party irrevocably
and unconditionally waives any right it may have to a trial by jury in respect of any legal action arising out of or relating
to this agreement or the transactions contemplated hereby. Any dispute, claim or controversy arising out of or relating to this
Agreement or the breach, termination, enforcement, interpretation or validity thereof, including the determination of the scope
or applicability of this agreement to arbitrate, shall be determined by final, binding arbitration in Orange County, California
before one (1) independent arbitrator; provided, however, that each Party retains its right to seek injunctive relief under applicable
law in a state court located in Orange County, California. The arbitration shall be administered by JAMS pursuant to JAMS’
Streamlined Arbitration Rules and Procedures. Judgment on the award may be entered in any court having jurisdiction. The prevailing
Party in any legal action (including arbitration) brought related to this Agreement, including exhibits, schedules, attachments,
appendices, and/or amendments thereto shall be entitled to recover its legal expenses incurred in connection therewith, including
without limitation reasonable attorney’s and expert witness fees and costs. The Parties hereby represent and acknowledge
that they have been provided with the opportunity to discuss and review the terms of this Agreement with their respective attorneys
before signing it and that they are freely and voluntarily signing this Agreement in exchange for the benefits provided herein.
The Parties further represent and acknowledge that they have been provided a reasonable period of time within which to review
the terms of this Agreement.

 

17.
Miscellaneous.

 

17.1
Waiver. The waiver by either Party of the performance of any covenant, condition or promise shall not invalidate this Agreement,
nor be considered a waiver of any other covenant, condition or promise. The waiver by either Party of the time for performing
any act shall not constitute a waiver of time for performing any other act or an identical act required to be performed at a later
time.

 

17.2
Amendments. All amendments and supplements to this Agreement must be in writing and executed by each party hereto.

 

    	Page 5 of 9

     

    

 

17.3
Counterparts. This Agreement may be executed in several counterparts, each of which shall be deemed an original, and all
of which together shall constitute one and the same instrument. However, this Agreement shall not be binding on a Party until
all Parties have executed this document, either all on one document or in counterparts.

 

17.4
Entire Agreement. It is understood and acknowledged that there are no oral agreements between the Parties hereto affecting
this Agreement and that this Agreement supersedes and cancels any and all previous negotiations, arrangements, agreements and
understandings, if any, between the Parties hereto with respect to the subject matter thereof, and none thereof shall be used
to interpret or construe this Agreement. This Agreement contains all of the terms, covenants, conditions, warranties and agreements
of the Parties relating in any manner to the subject matter hereof and shall be considered to be the only agreement between the
Parties hereto. All negotiations and oral agreements acceptable to both Parties have been merged into and are included herein.
There are no other representations or warranties between the Parties, and all reliance with respect to representations is based
totally upon the representations and agreements contained in this Agreement, if any.

 

17.5
Captions. The necessary grammatical changes required to make the provisions hereof apply either to corporations, limited
liability companies, partnerships or individuals, men or women, as the case may require, shall in all cases be assumed as though
in case fully expressed. The captions herein are for convenience only and shall not be deemed to limit, construe, affect or alter
the meaning hereof. If unenforceable, the remainder of this Agreement, or the application of such term, provision or condition
to persons or circumstances other than those with respect to which it is invalid or unenforceable, shall not be affected thereby,
and each and every other term, provision and condition of this Agreement shall be valid and enforceable to the fullest extent
possible permitted by law.

 

17.6
Assignment. The Parties agree that their rights and obligations under this Agreement may not be transferred or assigned
without the prior written of the other Party, except that either Party shall be permitted, without the other Party’s consent,
to assign or transfer this Agreement to any of its affiliates in connection with a merger or consolidation or a sale of all or
substantially all of its assets. This Agreement shall be binding and inure to the benefit of the Parties and their respective
legal representatives, heirs, administrators, executors, successors and permitted assigns.

 

17.7
Publicity. Neither Party shall issue a press release relating to the subject matter of this Agreement without the prior
written consent of the other Party, such consent not to be unreasonably withheld; provided, however, that Placement Agent shall
be allowed to refer to Client as a customer of Placement Agent in general advertising and marketing initiatives. Placement Agent
shall only have the right to use and market any participant/attendee data generated from the Services in an aggregated and personally
unidentifiable form.

 

17.8
Confidential Information. It is expressly agreed that the identities of any individual or entity and any other third parties
discussed and made available by Placement Agent in respect of the Transaction and any related business opportunity shall constitute
“Confidential Information” and Client and its Affiliates shall not without the prior written consent of Placement
Agent, to with withheld, conditioned or delayed in Placement Agent’s sole and absolute discretion: (a) directly or indirectly
initiate, solicit, negotiate, contract or enter into any business transactions, agreements or undertakings with any such third
party identified or introduced by Placement Agent; or (b) seek to by-pass, compete, avoid or circumvent the Placement Agent from
any business opportunity that relates to the Transaction by utilizing any Confidential Information or by otherwise exploiting
or deriving any benefit from the Confidential Information. Client each shall indemnify
and hold Placement Agent harmless from and against any damage, loss, cost or expense (including without limitation, reasonable
attorneys’ fees and costs incurred in the enforcement of the foregoing indemnity) arising out of a breach of this Section
17.8. This Section 17.8 shall survive the expiration or earlier termination of this Agreement.

 

    	Page 6 of 9

     

    

 

17.9
Electronic Signature. Signatures and initials required in this document may be executed via “wet” original
handwritten signature or initials, or via electronic signature or mark, which shall be binding on the Parties as originals, and
the executed signature pages may be delivered using pdf or similar file type transmitted via electronic mail, cloud based server,
e- signature technology or other similar electronic means, and any such transmittal shall constitute delivery of the executed
document for all purposes of this Agreement.

 

17.10
Authority. If either Party executes this Agreement as a partnership, corporation or limited liability company, then such
Party and the persons and/or entities executing this Agreement represent and warrant that: (a) it is a duly organized and existing
partnership, corporation or limited liability company, as the case may be, and is qualified to do business in the state in which
the business is located; (b) such persons and/or entities executing this Agreement are duly authorized to execute and deliver
this Agreement; and (c) this Agreement is binding in accordance with its terms.

 

[NO
FURTHER TEXT ON THIS PAGE; SIGNATURES ON FOLLOWING PAGE]

 

    	Page 7 of 9

     

    

 

IN
WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed as of the date first written above by their respective
officers thereunto duly authorized.

 

CLIENT

TAURIGA
SCIENCES, INC

a
Florida Corporation (C Corp.)

 

	By:	Tauriga
    Sciences, Inc.	 
	Name:	Seth
    M. Shaw	 
	Title:	Chief
    Executive Officer	 

 

[SIGNATURES
CONTINUED ON FOLLOWING PAGE]

 

    	Page 8 of 9

     

    

 

PLACEMENT
AGENT

 

KUSHCO
HOLDINGS, INC.

a
Nevada limited liability company

 

	By:	 	 
	Name:	STEPHEN
    Christoffersen	 
	Title:	Chief
    Financial Officer	 

 

    	Page 9 of 9Exhibit 4.1

 

PURCHASE
AGREEMENT

THIS
PURCHASE AGREEMENT (the “Agreement”), dated as of July 8, 2020, by and between ENOCHIAN BIOSCIENCES,
INC., a Delaware corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois
limited liability company (the “Investor”). Capitalized terms used herein and not otherwise defined herein
are defined in Section 1 hereof.

WHEREAS:

Subject
to the terms and conditions set forth in this Agreement, the Company wishes to sell to the Investor, and the Investor wishes to
buy from the Company, up to Twenty Million Dollars ($20,000,000) of the Company’s common stock, $0.0001 par value per share
(the “Common Stock”). The shares of Common Stock to be purchased hereunder are referred to herein as the “Purchase
Shares.”

NOW
THEREFORE, in consideration of the mutual covenants contained in this Agreement, and for other good and valuable consideration,
the receipt and adequacy of which are hereby acknowledged, the Company and the Investor hereby agree as follows:

		1.	CERTAIN
                                         DEFINITIONS.

For
purposes of this Agreement, the following terms shall have the following meanings:

(a)               
“Accelerated Purchase Date”
means, with respect to any Accelerated Purchase made pursuant to Section 2(b) hereof or any Additional Accelerated Purchase
pursuant to Section 2(c) hereof, the Business Day immediately following the applicable Purchase Date with respect to the
corresponding Regular Purchase made pursuant to Section 2(a) hereof.

(b)               
“Accelerated Purchase Period”
means, with respect to an Accelerated Purchase made pursuant to Section 2(b) hereof, such period of time on the Accelerated
Purchase Date beginning at the official open of trading on the Principal Market, and ending at the earliest of (i) the official
close of trading on the Principal Market on such Accelerated Purchase Date, (ii) such time that the total number (or volume) of
shares of Common Stock traded on the Principal Market has exceeded the quotient of (A) the Accelerated Purchase Share Amount,
divided by (B) 0.3, and (iii) such time on the Accelerated Purchase Date that the Sale Price has fallen below any minimum price
threshold set forth in the applicable Purchase Notice by the Company.

(c)               
 “Accelerated Purchase Share Amount”
means, with respect to an Accelerated Purchase made pursuant to Section 2(b) hereof or an Additional Accelerated Purchase
made pursuant to Section 2(c) hereof, the number of Purchase Shares directed by the Company to be purchased by the Investor
in an Purchase Notice, which number of Purchase Shares shall not exceed the lesser of (i) 300% of the applicable Regular Purchase
Share Limit for the corresponding Regular Purchase and (ii) 30% of the total volume of shares of Common Stock traded on the Principal
Market during the Accelerated Purchase Period or the Additional Accelerated Purchase Period, as applicable; provided, that
the parties may mutually agree to increase the Accelerated Purchase Share Amount for any Accelerated Purchase or Additional Accelerated
Purchase.

(d)               
“Additional Accelerated Purchase Period”
means, with respect to an Additional Accelerated Purchase pursuant to Section 2(c) hereof, such period of time on the Accelerated
Purchase Date beginning at the latest of (i) the end of the Accelerated Purchase Period for the corresponding Accelerated Purchase
made pursuant to Section 2(b) hereof on such Accelerated Purchase Date, (ii) the end of the Additional Accelerated Purchase
Period for the most recently completed prior Additional Accelerated Purchase pursuant to Section 2(c) hereof on such Accelerated
Purchase Date, as applicable, and (iii) the time at which all Purchase Shares for all prior Purchases, including, those effected
on the applicable Accelerated Purchase Date have theretofore been received by the Investor as DWAC Shares in accordance with this
Agreement, and ending at the earliest of (i) the official close of trading on the Principal Market on the Accelerated Purchase
Date, (ii) such time that the total number (or volume) of shares of Common Stock traded on the Principal Market has exceeded the
quotient of (A) the Accelerated Purchase Share Amount, and (B) 0.3, and (iii) such time that the Sale Price has fallen below any
minimum price threshold set forth in the applicable Purchase Notice by the Company.

    	 	1	 

     

    

(e)               
 “Available Amount” means,
initially, Twenty Million Dollars ($20,000,000) in the aggregate, which amount shall be reduced by the Purchase Amount each time
the Investor purchases shares of Common Stock pursuant to Section 2 hereof.

(f)                
“Bankruptcy Law” means Title
11, U.S. Code, or any similar federal or state law for the relief of debtors.

(g)               
 “Base Prospectus” means the
Company’s final base prospectus a preliminary form of which will be included in the Registration Statement in accordance
with Section 5(a), including the documents incorporated by reference therein, or any final base prospectus in any Registration
Statement filed after the date hereof to cover the sales of the Securities.

(h)               
 “Business Day” means any day
on which the Principal Market is open for trading, including any day on which the Principal Market is open for trading for a period
of time less than the customary time.

(i)                
“Closing Sale Price” means,
for any security as of any date, the last closing sale price for such security on the Principal Market as reported by the Principal
Market.

(j)                
“Confidential Information”
means any information disclosed by either party to the other party, either directly or indirectly, in writing, orally or by inspection
of tangible objects (including, without limitation, documents, prototypes, samples, plant and equipment), which is designated
as “Confidential,” “Proprietary” or some similar designation. Information communicated orally shall be
considered Confidential Information if such information is confirmed in writing as being Confidential Information within ten (10)
Business Days after the initial disclosure. Confidential Information may also include information disclosed to a disclosing party
by third parties. Confidential Information shall not, however, include any information which (i) was publicly known and made generally
available in the public domain prior to the time of disclosure by the disclosing party; (ii) becomes publicly known and made generally
available after disclosure by the disclosing party to the receiving party through no action or inaction of the receiving party;
(iii) is already in the possession of the receiving party without confidential restriction at the time of disclosure by the disclosing
party as shown by the receiving party’s files and records immediately prior to the time of disclosure; (iv) is obtained
by the receiving party from a third party without a breach of such third party’s obligations of confidentiality; or (v)
is independently developed by the receiving party without use of or reference to the disclosing party’s Confidential Information,
as shown by documents and other competent evidence in the receiving party’s possession.

(k)               
 “DTC” means The Depository
Trust Company, or any successor performing substantially the same function for the Company.

(l)                
“DWAC Shares” means shares
of Common Stock that are (i) issued in electronic form, (ii) freely tradable and transferable and without restriction on resale
and (iii) timely credited by the Company to the Investor’s or its designee’s specified Deposit/Withdrawal at Custodian
(DWAC) account with DTC under its Fast Automated Securities Transfer (FAST) Program, or any similar program hereafter adopted
by DTC performing substantially the same function.

    	 	2	 

     

    

(m)             
“Exchange Act” means the Securities
Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

(n)               
“Initial Prospectus Supplement”
means the prospectus supplement to the Base Prospectus complying to be prepared and filed by the Company with the SEC pursuant
to Rule 424(b) under the Securities Act and in accordance with Section 5(b), including the documents incorporated by reference
therein.

(o)               
“Material Adverse Effect”
means any material adverse effect on (i) the enforceability of any Transaction Document, (ii) the results of operations, assets,
business or financial condition of the Company and its Subsidiaries, taken as a whole, other than any material adverse effect
that resulted exclusively from (A) any change in the United States or foreign economies or securities or financial markets in
general that does not have a disproportionate effect on the Company and its Subsidiaries, taken as a whole, (B) any change that
generally affects the industry in which the Company and its Subsidiaries operate that does not have a disproportionate effect
on the Company and its Subsidiaries, taken as a whole, (C) any change arising in connection with earthquakes, hostilities, acts
of war, sabotage or terrorism or military actions or any escalation or material worsening of any such hostilities, acts of war,
sabotage or terrorism or military actions existing as of the date hereof, (D) any action taken by the Investor, its affiliates
or its or their successors and assigns with respect to the transactions contemplated by this Agreement, (E) the effect of any
change in applicable laws or accounting rules that does not have a disproportionate effect on the Company and its Subsidiaries,
taken as a whole, or (F) any change resulting from compliance with terms of this Agreement or the consummation of the transactions
contemplated by this Agreement, or (iii) the Company’s ability to perform in any material respect on a timely basis its
obligations under any Transaction Document to be performed as of the date of determination.

(p)               
“Maturity Date” means the
first day of the month immediately following the Thirty-Six (36) month anniversary of the Commencement Date.

(q)               
 “Person” means an individual
or entity including but not limited to any limited liability company, a partnership, a joint venture, a corporation, a trust,
an unincorporated organization and a government or any department or agency thereof.

(r)                
“Principal Market” means The
NASDAQ Capital Market; provided, however, that in the event the Company’s Common Stock is ever listed or traded on The NASDAQ
Global Market, The NASDAQ Global Select Market, the New York Stock Exchange, NYSE American, the NYSE Arca, the OTC Bulletin Board,
or the OTCQB or the OTCQX operated by the OTC Markets Group, Inc. (or any nationally recognized successor to any of the foregoing),
then the “Principal Market” shall mean such other market or exchange on which the Company’s Common Stock is
then listed or traded.

(s)                
“Prospectus” means the Base
Prospectus, as supplemented by any Prospectus Supplement (including the Initial Prospectus Supplement), including the documents
and information incorporated by reference therein.

(t)                
“Prospectus Supplement” means
any prospectus supplement to the Base Prospectus (including the Initial Prospectus Supplement) filed with the SEC pursuant to
Rule 424(b) under the Securities Act in connection with the transactions contemplated by this Agreement, including the documents
and information incorporated by reference therein.

    	 	3	 

     

    

(u)               
“Purchase” means any Regular
Purchase, Accelerated Purchase or Additional Accelerated Purchase, as applicable.

(v)               
“Purchase Amount” means, with
respect to any Regular Purchase, any Accelerated Purchase or any Additional Accelerated Purchase made hereunder, as applicable,
the portion of the Available Amount to be purchased by the Investor pursuant to Section 2 hereof.

(w)             
“Purchase Date” means, with
respect to a Regular Purchase made pursuant to Section 2(a) hereof, the Business Day on which the Investor receives, after
4:00 p.m., Eastern time on such Business Day, a valid Purchase Notice for such Regular Purchase in accordance with this Agreement.

(x)               
 “Purchase Notice” means a
notice delivered to the Investor pursuant to Section 2 with respect to any Regular Purchase, Accelerated Purchase or Additional
Accelerated Purchase, respectively.

(y)               
“Registration Rights Agreement”
means that certain Registration Rights Agreement, of even date herewith between the Company and the Investor.

(z)               
“Registration Statement” has
the meaning set forth in the Registration Rights Agreement.

(aa)            
 “Regular Purchase Share Limit”
means Fifty Thousand (50,000) Purchase Shares; provided, however, that (i) if the Closing Sale Price of the Common
Stock is not below $4.00 on the Purchase Date, the Regular Purchase Share Limit may be increased to up to Seventy-Five Thousand
(75,000) Purchase Shares, (ii) if the Closing Sale Price of the Common Stock is not below $6.00 on the Purchase Date, the Regular
Purchase Share Limit may be increased to up to One Hundred Thousand (100,000) Purchase Shares and (iii) if the Closing Sale Price
of the Common Stock is not below $8.00 on the Purchase Date, the Regular Purchase Share Limit may be increased to up to One Hundred
Twenty-Five Thousand (125,000) Purchase Shares, in each case to be adjusted following any reorganization, recapitalization, non-cash
dividend, stock split, reverse stock, split or other similar transaction effected with respect to the Common Stock; provided,
that if following such an adjustment the Regular Purchase Share Limit as adjusted would preclude the Company from delivering to
the Investor a Purchase Notice hereunder for a Purchase Amount equal to or greater than One Hundred Fifty Thousand Dollars ($150,000),
the Regular Purchase Share Limit shall equal the maximum number of Purchase Shares which would enable the Company to deliver to
the Investor a Purchase Notice for a Purchase Amount equal to, or as closely approximating without exceeding, One Hundred Fifty
Thousand Dollars ($150,000); provided, further, that the parties may mutually agree to increase the Regular Purchase
Share Limit for any Regular Purchase; and provided, further, however, that the Investor’s committed
obligation under any single Regular Purchase shall not exceed One Million Dollars ($1,000,000).

(bb)           
“Sale Price” means any trade
price for the shares of Common Stock on the Principal Market as reported by the Principal Market.

(cc)            
“SEC” means the U.S. Securities
and Exchange Commission.

(dd)           
“Securities” means, collectively,
the Purchase Shares and the Commitment Shares.

(ee)            
“Securities Act” means the
Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

(ff)              
 “Subsidiary” means any Person
the Company wholly-owns or controls, or in which the Company, directly or indirectly, owns a majority of the voting stock or similar
voting interest, in each case that would be disclosable pursuant to Item 601(b)(21) of Regulation S-K promulgated under the Securities
Act.

    	 	4	 

     

    

(gg)           
“Transaction Documents” means,
collectively, this Agreement and the schedules and exhibits hereto, the Registration Rights Agreement and the schedules and exhibits
thereto, and each of the other agreements, documents, certificates and instruments entered into or furnished by the parties hereto
in connection with the transactions contemplated hereby and thereby.

(hh)           
 “Transfer Agent” means Action
Stock Transfer, or such other Person who is then serving as the transfer agent for the Company in respect of the Common Stock.

(ii)              
“VWAP” means in respect of
an applicable Accelerated Purchase Date, the volume weighted average price of the Common Stock on the Principal Market, as reported
on the Principal Market or by another reputable source such as Bloomberg, L.P.

		2.	PURCHASE
                                         OF COMMON STOCK.

Subject
to the terms and conditions set forth in this Agreement, the Company has the right to sell to the Investor, and the Investor has
the obligation to purchase from the Company, Purchase Shares as follows:

 

(a)               
Commencement of Regular Purchases of Common
Stock. Upon the satisfaction of the conditions set forth in Sections 7 and 8 hereof (the “Commencement”
and the date of satisfaction of such conditions the “Commencement Date”) and thereafter, the Company shall
have the right, but not the obligation, to direct the Investor, by its delivery to the Investor of a Purchase Notice from time
to time on any Purchase Date, to purchase up to the Regular Purchase Share Limit at the lower of: (i) the lowest Sale Price of
the Common Stock on the applicable Purchase Date and (ii) the arithmetic average of the three (3) lowest Closing Sale Prices for
the Common Stock during the ten (10) consecutive Business Days ending on the Business Day immediately preceding such Purchase
Date (the “Purchase Price”) on each Purchase Date (each such purchase, a “Regular Purchase”).
The Company may deliver Purchase Notices to the Investor for multiple Regular Purchases on a Purchase Date subject to the second
sentence of Section 2(g).

(b)               
Accelerated Purchases. On any Purchase
Date, provided that the Company properly submitted a Purchase Notice for a Regular Purchase for a number of Purchase Shares not
less than the Regular Purchase Share Limit then in effect on such Purchase Date and subject to the terms and conditions of this
Agreement, the Company shall also have the right, but not the obligation, to direct the Investor, by its delivery to the Investor
of a Purchase Notice from time to time in accordance with this Agreement, to purchase the applicable Accelerated Purchase Share
Amount (each such purchase, an “Accelerated Purchase”) at the lower of (i) the Closing Sale Price of the Common
Stock on such applicable Accelerated Purchase Date and (ii) ninety-seven percent (97%) of the VWAP for the Accelerated Purchase
Period (the “Accelerated Purchase Price”). Within one (1) Business Day after completion of each Accelerated
Purchase Date for an Accelerated Purchase, the Investor will provide to the Company a written confirmation of such Accelerated
Purchase setting forth the applicable Accelerated Purchase Share Amount and Accelerated Purchase Price for such Accelerated Purchase.

(c)               
Additional Accelerated Purchases.  On
any Accelerated Purchase Date, provided that the Company properly submitted a Purchase Notice for an Accelerated Purchase and
subject to the terms and conditions of this Agreement, the Company shall also have the right, but not the obligation, to direct
the Investor, by its delivery to the Investor of a Purchase Notice from time to time in accordance with this Agreement, to purchase
the applicable Accelerated Purchase Share Amount (each such purchase, an “Additional Accelerated Purchase”)
at the Accelerated Purchase Price. The Company may deliver Purchase Notices to the Investor for multiple Additional Accelerated
Purchases on an Accelerated Purchase Date subject to the second sentence of Section 2(g).

    	 	5	 

     

    

(d)               
Payment for Purchase Shares.   
For each Regular Purchase, the Investor shall pay to the Company an amount equal to the Purchase Amount with respect to such Regular
Purchase as full payment for such Purchase Shares via wire transfer of immediately available funds on the same Business Day that
the Investor receives such Purchase Shares, if such Purchase Shares are received by the Investor before 1:00 p.m., Eastern time,
or, if such Purchase Shares are received by the Investor after 1:00 p.m., Eastern time, the next Business Day. Within one (1)
Business Day after completion of each Accelerated Purchase Date for an Accelerated Purchase or Additional Accelerated Purchase,
respectively, the Investor will provide to the Company a written confirmation of such Accelerated Purchase setting forth the applicable
Accelerated Purchase Share Amount and Accelerated Purchase Price for such Purchase. For each Accelerated Purchase and each Additional
Accelerated Purchase, the Investor shall pay to the Company an amount equal to the Purchase Amount with respect to such Purchase
as full payment for such Purchase Shares via wire transfer of immediately available funds on the second Business Day following
the date that the Investor receives the Purchase Shares for such Purchase. If the Company or the Transfer Agent shall fail for
any reason or for no reason to electronically transfer any Purchase Shares as DWAC Shares with respect to any Purchase within
three (3) Business Days following the receipt by the Company of the Purchase Price or Accelerated Purchase Price, as applicable,
for any Purchase therefor in compliance with this Section 2(d), and if on or after such Business Day the Investor purchases
(in an open market transaction or otherwise) shares of Common Stock to deliver in satisfaction of a sale by the Investor of Purchase
Shares in anticipation of receiving Purchase Shares from the Company with respect to such Purchase, then the Company shall, within
three (3) Business Days after the Investor’s request, either (i) pay cash to the Investor in an amount equal to the Investor’s
total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased (the “Cover
Price”), at which point the Company’s obligation to deliver such Purchase Shares as DWAC Shares shall terminate,
or (ii) promptly honor its obligation to deliver to the Investor such Purchase Shares as DWAC Shares and pay cash to the Investor
in an amount equal to the excess (if any) of the Cover Price over the total Purchase Amount paid by the Investor pursuant to this
Agreement for all of the Purchase Shares to be purchased by the Investor in connection with such purchases. All payments made
under this Agreement shall be made in lawful money of the United States of America or wire transfer of immediately available funds
to such account as the Company may from time to time designate by written notice in accordance with the provisions of this Agreement.

(e)               
Compliance with Rules of the Principal Market.
Notwithstanding anything in this Agreement to the contrary, and in addition to the limitations set forth in Section 2(f), the
Company shall not issue more than 9,299,480 shares (including the Commitment Shares) of Common Stock (the “Exchange Cap”)
under this Agreement, which equals 19.99% of the Company’s outstanding shares of Common Stock as of the date hereof, unless
stockholder approval is obtained to issue in excess of the Exchange Cap; provided, however, that the foregoing limitation shall
not apply if at any time the Exchange Cap is reached and at all times thereafter the average price paid for all shares of Common
Stock issued under this Agreement is equal to or greater than $4.0421 (the “Minimum Price”), a price equal
to the Nasdaq Official Closing Price immediately preceding the execution of this Agreement, as calculated in accordance with the
rules of the Principal Market (in such circumstance, for purposes of the Principal Market, the transaction contemplated hereby
would not be “below market” and the Exchange Cap would not apply). Notwithstanding the foregoing, the Company shall
not be required or permitted to issue, and the Investor shall not be required to purchase, any shares of Common Stock under this
Agreement if such issuance would violate the rules or regulations of the Principal Market. The Company may, in its sole discretion,
determine whether to obtain stockholder approval to issue more than 19.99% of its outstanding shares of Common Stock hereunder
if such issuance would require stockholder approval under the rules or regulations of the Principal Market. The Exchange Cap shall
be reduced, on a share-for-share basis, by the number of shares of Common Stock issued or issuable that may be aggregated with
the transactions contemplated by this Agreement under applicable rules of the Principal Market.

    	 	6	 

     

    

(f)                
Beneficial Ownership Limitation. Notwithstanding
anything to the contrary contained in this Agreement, the Company shall not issue or sell, and the Investor shall not purchase
or acquire, any shares of Common Stock under this Agreement which, when aggregated with all other shares of Common Stock
then beneficially owned by the Investor and its affiliates (as calculated pursuant to Section 13(d) of the Exchange Act and Rule
13d-3 promulgated thereunder) would result in the beneficial ownership by the Investor and its affiliates of more than 9.99%
of the then issued and outstanding shares of Common Stock (the “Beneficial Ownership Limitation”). Upon the
written or oral request of the Investor, the Company shall promptly (but not later than one (1) Business Day) confirm orally or
in writing to the Investor the amount of Common Stock then outstanding. The Investor and the Company shall each cooperate in good
faith in the determinations required hereby and the application hereof. The Investor’s written certification to the Company
of the applicability of the Beneficial Ownership Limitation, and the resulting effect thereof hereunder at any time, shall be
conclusive with respect to the applicability thereof and such result absent manifest error.

(g)               
Excess Share Limitations. If the Company
delivers any Purchase Notice for a Purchase Amount in excess of the limitations contained in this Section 2, such Purchase
Notice shall be void ab initio to the extent of the amount by which the number of Purchase Shares set forth in such Purchase
Notice exceeds the number of Purchase Shares which the Company is permitted to include in such Purchase Notice in accordance herewith,
and the Investor shall have no obligation to purchase such excess Purchase Shares in respect of such Purchase Notice; provided,
however, that the Investor shall remain obligated to purchase the number of Purchase Shares which the Company is permitted
to include in such Purchase Notice. If the Company delivers a Purchase Notice, and all Purchase Shares subject to all prior Purchases
have not theretofore been received by the Investor as DWAC Shares in accordance with this Agreement, such Purchase Notice shall
not be deemed to have been delivered and the Investor shall not be required to purchase any Purchase Shares until all Purchase
Shares for such prior Purchases have been received by the Investor as DWAC Shares. If any issuance of Purchase Shares would
result in the issuance of a fraction of a share of Common Stock, the Company shall round such fraction of a share of Common Stock
to the nearest whole share.

(h)               
Adjustments for Shares and Prices. Except
as specifically stated otherwise, all share-related and dollar-related limitations contained in this Section 2, shall be
adjusted to take into account any reorganization, recapitalization, non-cash dividend, stock split, reverse stock, split or other
similar transaction effected with respect to the Common Stock.

		3.	INVESTOR’S
                                         REPRESENTATIONS AND WARRANTIES.

The
Investor represents and warrants to the Company that as of the date hereof and as of the Commencement Date:

(a)               
Organization, Authority. Investor is an
entity duly organized, validly existing and in good standing under the laws of the jurisdiction of its organization, with the
requisite power and authority to enter into and to consummate the transactions contemplated by this Agreement and otherwise to
carry out its obligations hereunder and thereunder.

(b)               
Accredited Investor Status. The Investor
is an “accredited investor” as that term is defined in Rule 501(a)(3) of Regulation D promulgated under the Securities
Act.

    	 	7	 

     

    

(c)               
Investment Purpose. The Investor is acquiring
the Securities as principal for its own account for investment only and not with a view to or for distributing or reselling such
Securities or any part thereof in violation of the Securities Act or any applicable state securities law, has no present intention
of distributing any of such Securities in violation of the Securities Act or any applicable state securities law and has no direct
or indirect arrangement or understandings with any other Persons to distribute or regarding the distribution of such Securities
in violation of the Securities Act or any applicable state securities law (this representation and warranty not limiting the Investor’s
right to sell the Securities at any time pursuant to the Registration Statement described herein or otherwise in compliance with
applicable federal and state securities laws). The Investor is acquiring the Securities hereunder in the ordinary course of its
business.

(d)               
Information. The Investor understands
that its investment in the Securities involves a high degree of risk. The Investor (i) is able to bear the economic risk of an
investment in the Securities including a total loss thereof, (ii) has such knowledge and experience in financial and business
matters that it is capable of evaluating the merits and risks of the proposed investment in the Securities and (iii) has had an
opportunity to ask questions of and receive answers from the officers of the Company concerning the financial condition and business
of the Company and other matters related to an investment in the Securities. Neither such inquiries nor any other due diligence
investigations conducted by the Investor or its representatives shall modify, amend or affect the Investor’s right to rely
on the Company’s representations and warranties contained in Section 4 below. The Investor has sought such accounting,
legal and tax advice as it has considered necessary to make an informed investment decision with respect to its acquisition of
the Securities. The Investor acknowledges and agrees that neither the Company nor any of its Subsidiaries makes or has made any
representations or warranties with respect to the transactions contemplated hereby, other than those specifically set forth in
Section 4 hereof.

(e)               
No Governmental Review. The Investor understands
that no U.S. federal or state agency or any other government or governmental agency has passed on or made any recommendation or
endorsement of the Securities or the fairness or suitability of an investment in the Securities nor have such authorities passed
upon or endorsed the merits of the offering of the Securities.

(f)                
Validity; Enforcement. This Agreement
has been duly and validly authorized, executed and delivered on behalf of the Investor and is a valid and binding agreement of
the Investor enforceable against the Investor in accordance with its terms, subject as to enforceability to general principles
of equity and to applicable bankruptcy, insolvency, reorganization, moratorium, liquidation and other similar laws relating to,
or affecting generally, the enforcement of applicable creditors’ rights and remedies.

(g)               
Residency. The Investor is a resident
of the State of Illinois.

(h)               
No Short Selling. The Investor represents
and warrants to the Company that at no time prior to the date of this Agreement has any of the Investor, its agents, representatives
or affiliates engaged in or effected, in any manner whatsoever, directly or indirectly, any (i) “short sale” (as such
term is defined in Rule 200 of Regulation SHO of the Exchange Act) of the Common Stock or (ii) hedging transaction, which establishes
a net short position with respect to the Common Stock.

		4.	REPRESENTATIONS
                                         AND WARRANTIES OF THE COMPANY.

The
Company represents and warrants to the Investor that as of the date hereof and as of the Commencement Date:

    	 	8	 

     

    

(a)               
Organization and Qualification. The Company
and each of the Subsidiaries is an entity duly incorporated or otherwise organized, validly existing and in good standing under
the laws of the jurisdiction of its incorporation or organization, with the requisite corporate power and authority to own and
use its properties and assets and to carry on its business as currently conducted.  Neither the Company nor any Subsidiary
is in violation or default of any of the provisions of its respective certificate or articles of formation or incorporation, bylaws
or other organizational or charter documents except as would not be expected to result in a Material Adverse Effect.  Each
of the Company and the Subsidiaries is duly qualified to conduct business and is in good standing as a foreign corporation or
other entity in each jurisdiction in which the nature of the business conducted or property owned by it makes such qualification
necessary, except where the failure to be so qualified or in good standing, as the case may be, would not reasonably be expected
to result in a Material Adverse Effect, and no proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing
or seeking to revoke, limit or curtail such power and authority or qualification. The Company has no Subsidiaries except as set
forth in the Registration Statement.

(b)               
Authorization; Enforcement; Validity.
(i) The Company has the requisite corporate power and authority to enter into and perform its obligations under this Agreement
and each of the other Transaction Documents, and to issue the Securities in accordance with the terms hereof and thereof, (ii)
the execution and delivery of the Transaction Documents by the Company and the consummation by it of the transactions contemplated
hereby and thereby, including without limitation, the issuance of the Commitment Shares (as defined below in Section 5(f))
and the reservation for issuance and the issuance of the Purchase Shares issuable under this Agreement, have been duly authorized
by the Company's Board of Directors and no further consent or authorization is required by the Company, its Board of Directors
or any committee thereof, or its stockholders (except as set forth in Section 2(e) hereof), (iii) this Agreement has been,
and each other Transaction Document shall be on the Commencement Date, duly executed and delivered by the Company and (iv) this
Agreement constitutes, and each other Transaction Document upon its execution on behalf of the Company, shall constitute, the
valid and binding obligations of the Company enforceable against the Company in accordance with their terms, except as such enforceability
may be limited by general principles of equity or applicable bankruptcy, insolvency, reorganization, moratorium, liquidation or
similar laws relating to, or affecting generally, the enforcement of creditors' rights and remedies. The Board of Directors of
the Company has approved the resolutions (the “Signing Resolutions”) substantially in the form as set forth
as Exhibit B attached hereto to authorize this Agreement and the transactions contemplated hereby. The Signing Resolutions
are valid, in full force and effect and have not been modified or supplemented in any respect. The Company has delivered to the
Investor a true and correct copy of a unanimous written consent adopting the Signing Resolutions executed by all of the members
of the Board of Directors of the Company. Except as set forth in this Agreement, no other approvals or consents of the Company’s
Board of Directors, any other authorized committee thereof, and/or stockholders is necessary under applicable laws and the Company’s
Certificate of Incorporation in effect on the date hereof (the “Certificate of Incorporation”) and/or the Company’s
Bylaws in effect on the date hereof (the “Bylaws”) to authorize the execution and delivery of this Agreement
or any of the transactions contemplated hereby, including, but not limited to, the issuance of the Commitment Shares and the issuance
of the Purchase Shares.

    	 	9	 

     

    

(c)               
Capitalization. As of the date hereof,
the authorized capital stock of the Company is set forth in the SEC Documents (as defined below). Except as disclosed in the Registration
Statement or the SEC Documents, (i) no shares of the Company's capital stock are subject to preemptive rights or any other similar
rights or any liens or encumbrances suffered or permitted by the Company, (ii) there are no outstanding debt securities, (iii)
there are no outstanding options, warrants, scrip, rights to subscribe to, calls or commitments of any character whatsoever relating
to, or securities or rights convertible into, any shares of capital stock of the Company or any of its Subsidiaries, or contracts,
commitments, understandings or arrangements by which the Company or any of its Subsidiaries is or may become bound to issue additional
shares of capital stock of the Company or any of its Subsidiaries or options, warrants, scrip, rights to subscribe to, calls or
commitments of any character whatsoever relating to, or securities or rights convertible into, any shares of capital stock of
the Company or any of its Subsidiaries, (iv) there are no agreements or arrangements under which the Company or any of its Subsidiaries
is obligated to register the sale of any of their securities under the Securities Act (except the Registration Rights Agreement),
(v) there are no outstanding securities or instruments of the Company or any of its Subsidiaries which contain any redemption
or similar provisions, and there are no contracts, commitments, understandings or arrangements by which the Company or any of
its Subsidiaries is or may become bound to redeem a security of the Company or any of its Subsidiaries, (vi) there are no securities
or instruments containing anti-dilution or similar provisions that will be triggered by the issuance of the Securities as described
in this Agreement and (vii) the Company does not have any stock appreciation rights or “phantom stock” plans or agreements
or any similar plan or agreement. The Company has furnished to the Investor true and correct copies of the Certificate of Incorporation
and the Bylaws, and summaries of the terms of all securities convertible into or exercisable for Common Stock, if any, and copies
of any documents containing the material rights of the holders thereof in respect thereto.

(d)               
Issuance of Securities. Upon issuance
and payment therefor in accordance with the terms and conditions of this Agreement, the Securities shall be validly issued, fully
paid and nonassessable and free from all taxes, liens, charges, restrictions, rights of first refusal and preemptive rights with
respect to the issue thereof, with the holders being entitled to all rights accorded to a holder of Common Stock. 5,000,000 shares
of Common Stock have been duly authorized and reserved for issuance upon purchase under this Agreement as Purchase Shares.

(e)               
No Conflicts. The execution, delivery
and performance of the Transaction Documents by the Company and the consummation by the Company of the transactions contemplated
hereby and thereby (including, without limitation, the reservation for issuance and issuance of the Securities) will not (i) result
in a violation of the Certificate of Incorporation, any Certificate of Designations, Preferences and Rights of any outstanding
series of preferred stock of the Company or the Bylaws or (ii) conflict with, or constitute a default (or an event which with
notice or lapse of time or both would become a default) under, or give to others any rights of termination, amendment, acceleration
or cancellation of, any agreement, indenture or instrument to which the Company is a party, or result in a violation of any law,
rule, regulation, order, judgment or decree (including federal and state securities laws and regulations and the rules and regulations
of the Principal Market applicable to the Company) or by which any property or asset of the Company or any of its Subsidiaries
is bound or affected, except in the case of conflicts, defaults, terminations, amendments, accelerations, cancellations and violations
under clause (ii), which would not reasonably be expected to result in a Material Adverse Effect. Neither the Company nor any
of its Subsidiaries is in violation of any term of or is in default under any material contract, agreement, mortgage, indebtedness,
indenture, instrument, judgment, decree or order or any statute, rule or regulation applicable to the Company or its Subsidiaries,
except for possible conflicts, defaults, terminations or amendments that would not reasonably be expected to have a Material Adverse
Effect. The business of the Company and its Subsidiaries is not being conducted, and shall not be conducted, in violation of any
law, ordinance, regulation of any governmental entity, except for possible violations, the sanctions for which either individually
or in the aggregate would not reasonably be expected to have a Material Adverse Effect. Except as specifically contemplated by
this Agreement and as required under the Securities Act or applicable state securities laws and the rules and regulations of the
Principal Market, the Company is not required to obtain any consent, authorization or order of, or make any filing or registration
with, any court or governmental agency or any regulatory or self-regulatory agency in order for it to execute, deliver or perform
any of its obligations under or contemplated by the Transaction Documents in accordance with the terms hereof or thereof. Except
as set forth elsewhere in this Agreement, all consents, authorizations, orders, filings and registrations which the Company is
required to obtain pursuant to the preceding sentence shall be obtained or effected on or prior to the Commencement Date. Since
one year prior to the date hereof, the Company has not received nor delivered any notices or correspondence from or to the Principal
Market. The Principal Market has not commenced any delisting proceedings against the Company.

    	 	10	 

     

    

(f)                
SEC Documents; Financial Statements. The
Company has filed all reports, schedules, forms, statements and other documents required to be filed by the Company under the
Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the twelve months preceding the
date hereof (the foregoing materials, including the exhibits thereto and documents incorporated by reference therein, being collectively
referred to herein as the “SEC Documents”) on a timely basis or has received a valid extension of such time
of filing and has filed any such SEC Documents prior to the expiration of any such extension. As of their respective dates,
the SEC Documents complied in all material respects with the requirements of the Securities Act and the Exchange Act, as applicable.
None of the SEC Documents, when filed, contained any untrue statement of a material fact or omitted to state a material fact required
to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they
were made, not misleading. The financial statements of the Company included in the SEC Documents comply in all material respects
with applicable accounting requirements and the rules and regulations of the SEC with respect thereto as in effect at the time
of filing.  Such financial statements (i) have been prepared in accordance with United States generally accepted
accounting principles applied on a consistent basis during the periods involved (“GAAP”), except as may be
otherwise specified in such financial statements or the notes thereto and except that unaudited financial statements may not contain
all footnotes required by GAAP, and (ii) fairly present in all material respects the financial position of the Company and
its consolidated Subsidiaries as of and for the dates thereof and the results of operations and cash flows for the periods then
ended, subject, in the case of unaudited statements, to normal, immaterial, year-end audit adjustments. Except as publicly available
through the SEC’s Electronic Data Gathering, Analysis, and Retrieval system (EDGAR) or in connection with a confidential
treatment request submitted to the SEC, the Company has received no notices or correspondence from the SEC for the one year preceding
the date hereof other than SEC comment letters relating to the Company’s filings under the Exchange Act and the Securities
Act. There are no “open” SEC comments. To the Company’s knowledge, the SEC has not commenced any enforcement
proceedings against the Company or any of its Subsidiaries.

(g)               
Absence of Certain Changes. Except as
disclosed in the Registration Statement or the SEC Documents, since June 30, 2019, there has been no change that would constitute
a Material Adverse Effect in the business, properties, operations, financial condition or results of operations of the Company
or its Subsidiaries. The Company has not taken any steps, and does not currently expect to take any steps, to seek protection
pursuant to any Bankruptcy Law nor does the Company or any of its Subsidiaries have any knowledge or reason to believe that its
creditors intend to initiate involuntary bankruptcy or insolvency proceedings. The Company is financially solvent and is generally
able to pay its debts as they become due.

(h)               
Absence of Litigation. Except as disclosed
in the Registration Statement or the SEC Documents, there is no action, suit, proceeding, inquiry or investigation before or by
any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the Company or
any of its Subsidiaries, threatened against or affecting the Company, the Common Stock or any of the Company's Subsidiaries or
any of the Company's or the Company's Subsidiaries' officers or directors in their capacities as such, which would reasonably
be expected to have a Material Adverse Effect.

    	 	11	 

     

    

(i)                
Acknowledgment Regarding Investor’s
Status. The Company acknowledges and agrees that the Investor is acting solely in the capacity of arm’s length purchaser
with respect to the Transaction Documents and the transactions contemplated hereby and thereby. The Company further acknowledges
that the Investor is not acting as a financial advisor or fiduciary of the Company (or in any similar capacity) with respect to
the Transaction Documents and the transactions contemplated hereby and thereby and any advice given by the Investor or any of
its representatives or agents in connection with the Transaction Documents and the transactions contemplated hereby and thereby
is merely incidental to the Investor’s purchase of the Securities. The Company further represents to the Investor that the
Company’s decision to enter into the Transaction Documents has been based solely on the independent evaluation by the Company
and its representatives and advisors.

(j)                
No Aggregated Offering. Neither the Company,
nor any of its affiliates, nor any Person acting on its or their behalf has sold any security under circumstances that would reasonably
be expected to cause this offering of the Securities to be aggregated with prior offerings by the Company in a manner that would
require stockholder approval pursuant to the rules of the Principal Market on which any of the securities of the Company are listed
or designated. The issuance and sale of the Securities hereunder does not contravene the rules and regulations of the Principal
Market.

(k)               
Intellectual Property Rights. Except as
disclosed in the Registration Statement or the SEC Documents, the Company and its Subsidiaries own or possess adequate rights
or licenses to use all material trademarks, trade names, service marks, service mark registrations, service names, patents, patent
rights, copyrights, inventions, licenses, approvals, governmental authorizations, trade secrets and rights necessary to conduct
their respective businesses as now conducted. The Company and its Subsidiaries do not have any knowledge of any infringement by
the Company or its Subsidiaries of any material trademark, trade name rights, patents, patent rights, copyrights, inventions,
licenses, service names, service marks, service mark registrations, trade secret or other similar rights of others, or of any
such development of similar or identical trade secrets or technical information by others, and there is no claim, action or proceeding
being made or brought against, or to the Company's knowledge, being threatened against, the Company or its Subsidiaries regarding
trademark, trade name, patents, patent rights, invention, copyright, license, service names, service marks, service mark registrations,
trade secret or other infringement, which could reasonably be expected to have a Material Adverse Effect.

(l)                
Environmental Laws. The Company and its
Subsidiaries (i) are in compliance with any and all applicable foreign, federal, state and local laws and regulations relating
to the protection of human health and safety, the environment or hazardous or toxic substances or wastes, pollutants or contaminants
(“Environmental Laws”), (ii) have received all permits, licenses or other approvals required of them under
applicable Environmental Laws to conduct their respective businesses and (iii) are in compliance with all terms and conditions
of any such permit, license or approval, except where, in each of the three foregoing clauses, the failure to so comply could
not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect.

(m)             
Title. The Company does not own any real
property. The Company and the Subsidiaries have good and marketable title in all personal property solely owned by them that is
material to the business of the Company and the Subsidiaries, in each case free and clear of all liens, encumbrances and defects
(“Liens”) and, except for Liens as do not materially affect the value of such property and do not materially
interfere with the use made and proposed to be made of such property by the Company and the Subsidiaries and Liens for the payment
of federal, state or other taxes, the payment of which is neither delinquent nor subject to penalties.  Any real property
and facilities held under lease by the Company and the Subsidiaries are held by them under valid, subsisting and enforceable leases
with which the Company and the Subsidiaries are in compliance with such exceptions as are not material and do not interfere with
the use made and proposed to be made of such property and buildings by the Company and its Subsidiaries.

(n)               
Insurance. The Company and each of its
Subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and in such amounts
as management of the Company believes to be prudent and customary in the businesses in which the Company and its Subsidiaries
are engaged. Neither the Company nor any such Subsidiary has been refused any insurance coverage sought or applied for and neither
the Company nor any such Subsidiary has any reason to believe that it will not be able to renew its existing insurance coverage
as and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business
at a cost that would not materially and adversely affect the condition, financial or otherwise, or the earnings, business or operations
of the Company and its Subsidiaries, taken as a whole.

    	 	12	 

     

    

(o)               
Regulatory Permits. The Company and its
Subsidiaries possess all material certificates, authorizations and permits issued by the appropriate federal, state or foreign
regulatory authorities necessary to conduct their respective businesses as currently conducted, except where the failure to possess
such certificates, authorizations, or permits would not reasonably be expected to have a Material Adverse Effect, and neither
the Company nor any such Subsidiary has received any notice of proceedings relating to the revocation or modification of any such
material certificate, authorization or permit.

(p)               
Tax Status. The Company and each of its
Subsidiaries has made or filed all federal and state income and all other material tax returns, reports and declarations required
by any jurisdiction to which it is subject (unless and only to the extent that the Company and each of its Subsidiaries has set
aside on its books provisions reasonably adequate for the payment of all unpaid and unreported taxes) and has paid all taxes and
other governmental assessments and charges that are material in amount, shown or determined to be due on such returns, reports
and declarations, except those being contested in good faith and has set aside on its books provision reasonably adequate for
the payment of all taxes for periods subsequent to the periods to which such returns, reports or declarations apply. There are
no unpaid taxes in any material amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the
Company know of no basis for any such claim.

(q)               
Transactions With Affiliates. Except as
disclosed in the SEC Documents, to the Company’s knowledge, none of the Company’s stockholders, officers or directors
or any family member or affiliate of any of the foregoing, has either directly or indirectly an interest in, or is a party to,
any transaction that would be required to be disclosed as a related party transaction pursuant to Item 404 of Regulation S-K promulgated
under the Securities Act.

(r)                
Application of Takeover Protections. The
Company and its Board of Directors have taken or will take prior to the Commencement Date all necessary action, if any, in order
to render inapplicable any control share acquisition, business combination, poison pill (including any distribution under a rights
agreement) or other similar anti-takeover provision under the Certificate of Incorporation or the laws of the state of its incorporation
which is or could become applicable to the Investor as a result of the transactions contemplated by this Agreement, including,
without limitation, the Company’s issuance of the Securities and the Investor’s ownership of the Securities.

(s)                
Disclosure. Except with respect to the
material terms and conditions of the transactions contemplated by the Transaction Documents that will be timely publicly disclosed
by the Company, the Company confirms that neither it nor any other Person acting on its behalf has provided the Investor or its
agents or counsel with any information that it believes constitutes or might constitute material, non-public information which
is not otherwise disclosed in the Registration Statement or the SEC Documents.   The Company understands and confirms
that the Investor will rely on the foregoing representation in effecting purchases and sales of securities of the Company.  All
of the disclosure furnished by or on behalf of the Company to the Investor regarding the Company, its business and the transactions
contemplated hereby, including the disclosure schedules to this Agreement, taken as a whole, is true and correct in all material
respects and does not contain any untrue statement of a material fact or omit to state any material fact necessary in order to
make the statements made therein, in light of the circumstances under which they were made, not misleading. The Company acknowledges
and agrees that the Investor neither makes nor has made any representations or warranties with respect to the transactions contemplated
hereby other than those specifically set forth in Section 3 hereof.

(t)                
Foreign Corrupt Practices. Neither the
Company, nor to the knowledge of the Company, any agent or other Person acting on behalf of the Company, has (i) directly or indirectly,
used any funds for unlawful contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political
activity, (ii) made any unlawful payment to foreign or domestic government officials or employees or to any foreign or domestic
political parties or campaigns from corporate funds, (iii) failed to disclose fully any contribution made by the Company (or made
by any Person acting on its behalf of which the Company is aware) which is in violation of law, or (iv) violated in any material
respect any provision of the Foreign Corrupt Practices Act of 1977, as amended.

    	 	13	 

     

    

(u)               
DTC Eligibility. The Company, through
the Transfer Agent, currently participates in the DTC Fast Automated Securities Transfer (FAST) Program and the Common Stock can
be transferred electronically to third parties via the DTC Fast Automated Securities Transfer (FAST) Program.

(v)               
Sarbanes-Oxley. The Company is in compliance
with all provisions of the Sarbanes-Oxley Act of 2002, as amended, which are applicable to it as of the date hereof.

(w)             
Certain Fees. No brokerage or finder’s
fees or commissions are or will be payable by the Company to any broker, financial advisor or consultant, finder, placement agent,
investment banker, bank or other Person with respect to the transactions contemplated by the Transaction Documents. The Investor
shall have no obligation with respect to any fees or with respect to any claims made by or on behalf of other Persons for fees
of a type contemplated in this Section 4(w) that may be due in connection with the transactions contemplated by the Transaction
Documents. The Company shall pay, and hold the Investor harmless against, any liability, loss or expense (including, without limitation,
attorneys’ fees and out of pocket expenses) arising in connection with any such claim.

(x)               
Investment Company. The Company is not
required to be registered as, and immediately after receipt of payment for the Securities will not be required to be registered
as, an “investment company” within the meaning of the Investment Company Act of 1940, as amended.

(y)               
Listing and Maintenance Requirements.
The Common Stock is registered pursuant to Section 12(b) of the Exchange Act, and the Company has taken no action designed
to, or which to its knowledge is likely to have the effect of, terminating the registration of the Common Stock pursuant to the
Exchange Act nor has the Company received any notification that the SEC is currently contemplating terminating such registration.
The Company has not, in the twelve (12) months preceding the date hereof, received any notice from any Person to the effect that
the Company is not in compliance with the listing or maintenance requirements of the Principal Market, and has no reason to believe
that it will not in the foreseeable future continue to be, in compliance with all such listing and maintenance requirements. The
Company has not been since June 30, 2018, and currently is not, an Ineligible Issuer (as defined in Rule 405 of the Exchange Act).

(z)               
Accountants. The Company’s accountants
are set forth in the SEC Documents and, to the knowledge of the Company, such accountants are an independent registered public
accounting firm as required by the Securities Act.

(aa)            
No Market Manipulation. The Company has
not, and to its knowledge no Person acting on its behalf has, (i) taken, directly or indirectly, any action designed to cause
or to result in the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale
of any of the Securities, (ii) sold, bid for, purchased, or, paid any compensation for soliciting purchases of, any of the Securities,
or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any other securities of the Company.

(bb)           
Benefit Plans; Labor Matters. Each benefit
and compensation plan, agreement, policy and arrangement that is maintained, administered or contributed to by the Company for
current or former employees or directors of, or independent contractors with respect to, the Company has been maintained in compliance
with its terms and the requirements of any applicable statutes, orders, rules and regulations, and the Company has complied in
all material respects with all applicable statutes, orders, rules and regulations in regard to such plans, agreements, policies
and arrangements. Each stock option granted under any equity incentive plan of the Company (each, a “Stock Plan”)
was granted with a per share exercise price no less than the market price per common share on the grant date of such option in
accordance with the rules of the Principal Market, and no such grant involved any “back-dating,” “forward-dating”
or similar practice with respect to the effective date of such grant; each such option (i) was granted in compliance in all
material respects with Applicable Laws and with the applicable Stock Plan(s), (ii) was duly approved by the Board of Directors
or a duly authorized committee thereof, and (iii) has been properly accounted for in the Company’s financial statements
and disclosed, to the extent required, in the Company’s filings or submissions with the SEC, and the Principal Market. No
labor problem or dispute with the employees of the Company exists or is threatened or imminent, and the Company is not aware of
any existing or imminent labor disturbance by the employees of any of its principal suppliers or contractors, that would have
a Material Adverse Effect.

    	 	14	 

     

    

(cc)            
Regulatory. During the 12-month period
immediately preceding the Execution Date, except as described in the SEC Documents, the Company and each of its Subsidiaries:
(A) is and at all times has been in material compliance with all applicable U.S. and foreign statutes, rules, or regulations applicable
to Company and its Subsidiaries (“Applicable Laws”), except as would not, individually or in the aggregate,
reasonably be expected to result in a Material Adverse Effect; (B) have not received any written notice of adverse finding, warning
letter, untitled letter or other correspondence or notice from the U.S. Food and Drug Administration or any other federal, state,
or foreign governmental authority having authority over the Company (“Governmental Authority”) alleging or
asserting material noncompliance with any Applicable Laws or any licenses, certificates, approvals, clearances, authorizations,
permits and supplements or amendments thereto required by any such Applicable Laws (“Authorizations”); (C)
possess all material Authorizations and such material Authorizations are valid and in full force and effect and, to the Company’s
knowledge, are not in violation of any term of any such material Authorizations; (D) have not received written notice of any claim,
action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any Governmental Authority or
third party alleging that any product, operation or activity is in violation of any Applicable Laws or Authorizations and have
no knowledge that any such Governmental Authority or third party is considering any such claim, litigation, arbitration, action,
suit, investigation or proceeding; (E) have not received written notice that any Governmental Authority has taken, is taking or
intends to take action to limit, suspend, modify or revoke any Authorizations and the Company has no knowledge that any such Governmental
Authority is considering such action; and (F) have filed, obtained, maintained or submitted all material reports, documents, forms,
notices, applications, records, claims, submissions and supplements or amendments as required by any Applicable Laws or material
Authorizations and that all such reports, documents, forms, notices, applications, records, claims, submissions and supplements
or amendments were complete and correct in all material respects on the date filed (or were corrected or supplemented by a subsequent
submission). During the 12-month period immediately preceding the Execution Date, to the Company’s knowledge, the studies,
tests and preclinical studies and clinical trials conducted by or on behalf of the Company were and, if still pending, are, in
all material respects, being conducted in accordance with experimental protocols, procedures and controls pursuant to accepted
professional scientific standards and all Applicable Laws, including, without limitation, the United States Federal Food, Drug,
and Cosmetic Act or any other federal, provincial, state, local or foreign governmental or quasi-governmental body exercising
comparable authority; the descriptions of the results of such studies, tests and trials contained in the SEC Documents are accurate
and complete in all material respects and fairly present the data derived from such studies, tests and trials; and the descriptions
in the SEC Documents of the results of such clinical trials are consistent in all material respects with such results and to the
Company’s knowledge there are no other studies or other clinical trials whose results are materially inconsistent with or
otherwise materially call into question the results described or referred to in the SEC Documents. The Company has concluded that
it uses commercially reasonable efforts to review, from time to time, the progress and results of the studies, tests and preclinical
studies and clinical trials and, based upon (i) the information provided to the Company by the third parties conducting such studies,
tests, preclinical studies and clinical trials that are described in the SEC Documents and the Company’s review of such
information, and (ii) the Company’s actual knowledge, the Company reasonably believes that the descriptions of the results
of such studies, tests, preclinical studies and clinical trials are accurate and complete in all material respects.

(dd)           
Shell Company Status. The Company is not,
and has not been in the past twenty-four (24) months been, an issuer identified in Rule 144(i)(1) under the Securities Act and
has filed with the SEC current “Form 10 information” (as defined in Rule 144(i)(3) under the Securities Act) at least
twelve (12) months prior to the date of this Agreement reflecting its status as an entity that is no longer an issuer identified
in Rule 144(i)(1) under the Securities Act.

    	 	15	 

     

    

		5.	COVENANTS.

(a)               
Registration Statement. The Company shall,
within ten (10) Business Days prepare and file with the SEC in accordance with the provisions of the Securities Act the Registration
Statement. The Company shall use its best efforts to have the Registration Statement declared effective at the earliest possible
date. The “Plan of Distribution” section of the Prospectus shall permit the issuance of the Securities hereunder.
The Base Prospectus and any Prospectus Supplement thereto, at the time such Base Prospectus or such Prospectus Supplement thereto
are filed and on the Commencement Date, complied and will comply in all material respects with the requirements of the Securities
Act and will not contain an untrue statement of a material fact or omit to state a material fact necessary in order to make the
statements therein, in light of the circumstances under which they were made, not misleading; provided that this representation
and warranty shall not apply to statements in or omissions from any Prospectus Supplement made in reliance upon and in conformity
with information relating to the Investor furnished to the Company in writing by or on behalf of the Investor expressly for use
therein. The Company meets and shall meet at the time of filing of the Registration Statement, and of any Prospectus or Prospectus
Supplement thereunder, all of the requirements for the use of a registration statement on Form S-3 pursuant to the Securities
Act for the offering and sale of the Securities contemplated by this Agreement without reliance on General Instruction I.B.6.
of Form S-3, and the SEC shall not have notified the Company of any objection to the use of the form of the Registration Statement
pursuant to Rule 401(g)(1) of the Securities Act. The Registration Statement, as of its effective date, shall meet the requirements
set forth in Rule 415(a)(1)(x) pursuant to the Securities Act. The Company has not distributed any offering material in connection
with the offering and sale of any of the Securities, and, until the Investor does not hold any of the Securities, shall not distribute
any offering material in connection with the offering and sale of any of the Securities, to or by the Investor, in each case,
other than the Registration Statement or any amendment thereto, the Prospectus or any Prospectus Supplement required pursuant
to applicable law or the Transaction Documents. The Company has not made, and agrees that unless it obtains the prior written
consent of the Investor it will not make, an offer relating to the Securities that would constitute a “free writing prospectus”
as defined in Rule 405 under the Securities Act.

(b)               
Filing of Current Report and Initial Prospectus
Supplement. The Company agrees that it shall, within the time required under the Exchange Act, file with the SEC a current
report on Form 8-K relating to the transactions contemplated by, and describing the material terms and conditions of, the Transaction
Documents (the “Current Report”). The Company further agrees that it shall, within the time required under
Rule 424(b) under the Securities Act, file with the SEC the Initial Prospectus Supplement pursuant to Rule 424(b) under the Securities
Act specifically relating to the transactions contemplated by, and describing the material terms and conditions of, the Transaction
Documents, containing information previously omitted at the time of effectiveness of the Registration Statement in reliance on
Rule 430B under the Securities Act, and disclosing all information relating to the transactions contemplated hereby required to
be disclosed in the Registration Statement and the Prospectus as of the date of the Initial Prospectus Supplement, including,
without limitation, information required to be disclosed in the section captioned “Plan of Distribution” in the Prospectus.
The Investor acknowledges that it will be identified in the Initial Prospectus Supplement as an underwriter within the meaning
of Section 2(a)(11) of the Securities Act. The Company shall permit the Investor to review and comment upon the Current Report
and the Initial Prospectus Supplement at least two (2) Business Days prior to their filing with the SEC, the Company shall give
due consideration to all such comments, and the Company shall not file the Current Report or the Initial Prospectus Supplement
with the SEC in a form to which the Investor reasonably objects. The Investor shall use its reasonable best efforts to comment
upon the Current Report and the Initial Prospectus Supplement within one (1) Business Day from the date the Investor receives
the final pre-filing draft version thereof from the Company. The Investor shall furnish to the Company such information regarding
itself, the Securities held by it and the intended method of distribution thereof, including any arrangement between the Investor
and any other Person relating to the sale or distribution of the Securities, as shall be reasonably requested by the Company in
connection with the preparation and filing of the Current Report and the Initial Prospectus Supplement, and shall otherwise cooperate
with the Company as reasonably requested by the Company in connection with the preparation and filing of the Current Report and
the Initial Prospectus Supplement with the SEC.

    	 	16	 

     

    

(c)               
Blue Sky. The Company shall take all such
action, if any, as is necessary in order to obtain an exemption for or to register or qualify (i) the issuance of the Commitment
Shares and the sale of the Purchase Shares to the Investor under this Agreement and (ii) any subsequent resale of all Commitment
Shares and all Purchase Shares by the Investor, in each case, under applicable securities or “Blue Sky” laws of the
states of the United States in such states as is reasonably requested by the Investor from time to time, and shall provide evidence
of any such action so taken to the Investor.

(d)               
Listing/DTC. The Company shall promptly
secure the listing of all of the Purchase Shares and Commitment Shares to be issued to the Investor hereunder on the Principal
Market (subject to official notice of issuance) and upon each other national securities exchange or automated quotation system,
if any, upon which the Common Stock is then listed, and shall use reasonable best efforts to maintain, so long as any shares of
Common Stock shall be so listed, such listing of all such Securities from time to time issuable hereunder. The Company shall maintain
the listing of the Common Stock on the Principal Market and shall comply in all respects with the Company’s reporting, filing
and other obligations under the bylaws or rules and regulations of the Principal Market. Neither the Company nor any of its Subsidiaries
shall take any action that would reasonably be expected to result in the delisting or suspension of the Common Stock on the Principal
Market. The Company shall promptly, and in no event later than the following Business Day, provide to the Investor copies of any
notices it receives from the Principal Market regarding the continued eligibility of the Common Stock for listing on the Principal
Market; provided, however, that the Company shall not be required to provide the Investor copies of any such notice that the Company
reasonably believes constitutes material non-public information and the Company would not be required to publicly disclose such
notice in any report or statement filed with the SEC under the Exchange Act (including on Form 8-K) or the Securities Act. The
Company shall pay all fees and expenses in connection with satisfying its obligations under this Section 5(d). The Company
shall take all action necessary to ensure that its Common Stock can be transferred electronically as DWAC Shares.

(e)               
Prohibition of Short Sales and Hedging Transactions.
The Investor agrees that beginning on the date of this Agreement and ending on the date of termination of this Agreement as provided
in Section 11, the Investor and its agents, representatives and affiliates shall not in any manner whatsoever enter into
or effect, directly or indirectly, any (i) “short sale” (as such term is defined in Rule 200 of Regulation SHO of
the Exchange Act) of the Common Stock or (ii) hedging transaction, which establishes a net short position with respect to the
Common Stock.

    	 	17	 

     

    

(f)                
Issuance of Commitment Shares. In consideration
for the Investor’s execution and delivery of this Agreement, the Company shall cause to be issued to the Investor a total
of 139,567 shares of Common Stock (the “Commitment Shares”) and shall deliver to the Transfer Agent the Irrevocable
Transfer Agent Instructions with respect to the issuance of such Commitment Shares. For the avoidance of doubt, all of the Commitment
Shares shall be fully earned as of the date of this Agreement, whether or not the Commencement shall occur or any Purchase Shares
are purchased by the Investor under this Agreement and irrespective of any subsequent termination of this Agreement.

(g)               
Due Diligence; Non-Public Information.
The Investor shall have the right, from time to time as the Investor may reasonably deem appropriate, and upon reasonable advance
notice to the Company, to perform reasonable due diligence on the Company during normal business hours. The Company and its officers
and employees shall provide information and reasonably cooperate with the Investor in connection with any reasonable request by
the Investor related to the Investor's due diligence of the Company. Each party hereto agrees not to disclose any Confidential
Information of the other party to any third party and shall not use the Confidential Information for any purpose other than in
connection with, or in furtherance of, the transactions contemplated hereby. Each party hereto acknowledges that the Confidential
Information shall remain the property of the disclosing party and agrees that it shall take all reasonable measures to protect
the secrecy of any Confidential Information disclosed by the other party. The receiving party may disclose Confidential Information
to the extent such information is required to be disclosed by law, regulation or order of a court of competent jurisdiction or
regulatory authority, provided that the receiving party shall promptly notify the disclosing party when such requirement to disclose
arises, and shall cooperate with the disclosing party so as to enable the disclosing party to: (i) seek an appropriate protective
order; and (ii) make any applicable claim of confidentiality in respect of such Confidential Information; and provided, further,
that the receiving party shall disclose Confidential Information only to the extent required by the protective order or other
similar order, if such an order is obtained, and, if no such order is obtained, the receiving party shall disclose only the minimum
amount of such Confidential Information required to be disclosed in order to comply with the applicable law, regulation or order.
In addition, any such Confidential Information disclosed pursuant to this Section 5(g) shall continue to be deemed Confidential
Information. Notwithstanding anything in this Agreement to the contrary, the Company and the Investor agree that neither the Company
nor any other Person acting on its behalf shall provide the Investor or its agents or counsel with any information that constitutes
or may reasonably be considered to constitute material, non-public information, unless a simultaneous public announcement thereof
is made by the Company in the manner contemplated by Regulation FD. In the event of a breach of the foregoing covenant by the
Company or any Person acting on its behalf (as determined in the reasonable good faith judgment of the Investor), in addition
to any other remedy provided herein or in the other Transaction Documents, if the Investor is holding any Securities at the time
of the disclosure of such material non-public information, the Investor shall have the right to make a public disclosure, in the
form of a press release, public advertisement or otherwise, of such material, non-public information without the prior approval
by the Company; provided the Investor shall have first provided notice to the Company that it believes it has received information
that constitutes material, non-public information, the Company shall have at least twenty-four (24) hours to either publicly disclose
such material, non-public information or to demonstrate to the Investor that such information does not constitute material, non-public
information. The Investor shall not have any liability to the Company, any of its Subsidiaries, or any of their respective directors,
officers, employees, stockholders or agents, for any such disclosure. The Company understands and confirms that the Investor shall
be relying on the foregoing covenants in effecting transactions in securities of the Company.

(h)               
 Purchase Records. The Investor and the
Company shall each maintain records showing the remaining Available Amount at any given time and the dates and Purchase Amounts
for each Regular Purchase, Accelerated Purchase and Additional Accelerated Purchase or shall use such other method, reasonably
satisfactory to the Investor and the Company.

    	 	18	 

     

    

(i)                
Taxes. The Company shall pay any and all
transfer, stamp or similar taxes that may be payable with respect to the issuance and delivery of any shares of Common Stock to
the Investor made under this Agreement.

(j)                
No Aggregation. From and after the date
of this Agreement, neither the Company, nor or any of its affiliates will, and the Company shall use its reasonable best efforts
to ensure that no Person acting on their behalf will, directly or indirectly, make any offers or sales of any security or solicit
any offers to buy any security, under circumstances that would cause this offering of the Securities by the Company to the Investor
to be aggregated with other offerings by the Company in a manner that would require stockholder approval pursuant to the rules
of the Principal Market on which any of the securities of the Company are listed or designated, unless in the case of this clause
(ii), stockholder approval is obtained before the closing of such subsequent transaction in accordance with the rules of such
Principal Market.

(k)               
Use of Proceeds. The Company will use
the net proceeds from the offering as described in the Prospectus.

(l)                
Other Transactions. The Company shall
not enter into, announce or recommend to its stockholders any agreement, plan, arrangement or transaction in or of which the terms
thereof would restrict, materially delay, conflict with or impair the ability or right of the Company to perform its obligations
under the Transaction Documents, including, without limitation, the obligation of the Company to deliver the Purchase Shares and
the Commitment Shares to the Investor in accordance with the terms of the Transaction Documents.

(m)             
No Variable Rate Transactions. From and
after the date of this Agreement until the later of (i) the thirty-sixth (36) month anniversary of the date of this Agreement
and (ii) the thirty-sixth (36) month anniversary of the Commencement Date (if the Commencement has occurred), in any case
irrespective of any earlier termination of this Agreement, the Company shall be prohibited from effecting or entering into an
agreement to effect any issuance by the Company or any of its Subsidiaries of Common Stock or Common Stock Equivalents (or a combination
of units thereof) involving a Variable Rate Transaction, other than in connection with an Exempt Issuance. The Investor shall
be entitled to obtain injunctive relief against the Company and its Subsidiaries to preclude any such issuance, which remedy shall
be in addition to any right to collect damages, without the necessity of showing economic loss and without any bond or other security
being required. “Common Stock Equivalents” means any securities of the Company or its Subsidiaries which entitle
the holder thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, rights, options,
warrants or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the
holder thereof to receive, Common Stock. “Variable Rate Transaction” means a transaction in which the Company
(i) issues or sells any debt or equity securities that are convertible into, exchangeable or exercisable for, or include the right
to receive additional shares of Common Stock or Common Stock Equivalents either (A) at a conversion price, exercise price, exchange
rate or other price that is based upon and/or varies with the trading prices of or quotations for the Common Stock at any time
after the initial issuance of such debt or equity securities (including, without limitation, pursuant to any “cashless exercise”
provisions, but not including any standard anti-dilution protection for any reorganization, recapitalization, non-cash dividend,
stock split or other similar transaction), or (B) with a conversion, exercise or exchange price that is subject to being reset
at some future date after the initial issuance of such debt or equity security or upon the occurrence of specified or contingent
events directly or indirectly related to the business of the Company or the market for the Common Stock (including, without limitation,
any “full ratchet” or “weighted average” anti-dilution provisions), (ii) issues or sells any debt or equity
securities, including without limitation, Common Stock or Common Stock Equivalents, either (A) at a price that is subject to being
reset at some future date after the initial issuance of such debt or equity security or upon the occurrence of specified or contingent
events directly or indirectly related to the business of the Company or the market for the Common Stock (other than standard anti-dilution
protection for any reorganization, recapitalization, non-cash dividend, stock split or other similar transaction), or (B) that
is subject to or contains any put, call, redemption, buy-back, price-reset or other similar provision or mechanism (including,
without limitation, a “Black-Scholes” put or call right) that provides for the issuance of additional debt or equity
securities of the Company or the payment of cash by the Company, or (iii) enters into any agreement, including, but not limited
to, an “equity line”, “at-the-market offering” or other continuous offering or similar offering of Common
Stock or Common Stock Equivalents, whereby the Company may sell Common Stock or Common Stock Equivalents at a future determined
price. “Exempt Issuance” means the issuance of (a) Common Stock or Common Stock Equivalents to employees, officers,
directors or vendors of the Company pursuant to any stock or option plan duly adopted for such purpose, by the Board of Directors
or a majority of the members of a committee of directors established for such purpose, (b) securities upon the exercise or exchange
of or conversion of any Securities issued hereunder, and/or other securities exercisable or exchangeable for or convertible into
Common Stock issued and outstanding on the date of this Agreement, provided that such securities have not been amended since the
date of this Agreement to increase the number of such securities or to decrease the exercise price, exchange price or conversion
price of such securities, (c) securities issued pursuant to acquisitions, divestitures, licenses, partnerships, collaborations
or strategic transactions approved by the Board of Directors or a majority of the members of a committee of directors established
for such purpose, which acquisitions, divestitures, licenses, partnerships, collaborations or strategic transactions can have
a Variable Rate Transaction component, provided that any such issuance shall only be to a Person (or to the equity holders of
a Person) which is, itself or through its subsidiaries, an operating company or an asset in a business synergistic with the business
of the Company and shall provide to the Company additional benefits in addition to the investment of funds, but shall not include
a transaction in which the Company is issuing securities primarily for the purpose of raising capital or to an entity whose primary
business is investing in securities, or (d) shares of Common Stock issued and sold pursuant to any “at-the-market offering”
of Common Stock through a registered broker-dealer pursuant to an agreement executed from and after the date of this Agreement.

    	 	19	 

     

    

(n)               
Publicity. The Company shall afford the
Investor and its counsel with the opportunity to review and comment upon, shall consult with the Investor and its counsel on the
form and substance of, and shall give due consideration to all such comments from the Investor or its counsel on, any press release,
SEC filing or any other public disclosure by or on behalf of the Company that relates to the Investor, its purchases hereunder
or any aspect of the Transaction Documents or the transactions contemplated thereby, not less than twenty-four (24) hours prior
to the issuance, filing or public disclosure thereof; provided that the Company shall not be required to provide to the
Investor any disclosures that are materially similar to those previously reviewed by the Investor. The Investor must be provided
with a substantially final version of any such press release, SEC filing or other public disclosure at least twenty-four (24)
hours prior to any release, filing or use by the Company thereof. The Company agrees and acknowledges that its failure to fully
comply with this provision constitutes a Material Adverse Effect.

		6.	TRANSFER
                                         AGENT INSTRUCTIONS.

On
the Commencement Date, the Company shall issue to the Transfer Agent (and any subsequent transfer agent) irrevocable instructions,
in the form substantially similar to those used by the Investor in substantially similar transactions, to issue the Purchase Shares
and the Commitment Shares in accordance with the terms of this Agreement (the “Irrevocable Transfer Agent Instructions”).
All Securities to be issued to or for the benefit of the Investor pursuant to this Agreement shall be issued as DWAC Shares. The
Company warrants to the Investor that no instruction other than the Irrevocable Transfer Agent Instructions referred to in this
Section 6 will be given by the Company to the Transfer Agent with respect to the Securities, and the Securities shall otherwise
be freely transferable on the books and records of the Company.

		7.	CONDITIONS
                                         TO THE COMPANY’S RIGHT TO COMMENCE SALES OF SHARES OF COMMON STOCK.

The
right of the Company hereunder to commence sales of the Purchase Shares on the Commencement Date is subject to the satisfaction
or, where legally permissible, the waiver of each of the following conditions:

    	 	20	 

     

    

(a)               
The Investor shall have executed each of the
Transaction Documents and delivered the same to the Company;

(b)               
No stop order with respect to the Registration
Statement shall be pending or threatened by the SEC;

(c)               
The Common Stock shall be listed on the Principal
Market, and all Securities to be issued by the Company to the Investor under the Transaction Documents shall have been approved
for listing on the Principal Market in accordance with the applicable rules and regulations of the Principal Market, subject only
to official notice of issuance; and

(d)               
The representations and warranties of the Investor
shall be true and correct in all material respects (except to the extent that any of such representations and warranties is already
qualified as to materiality in Section 3 above, in which case, such representations and warranties shall be true and correct
without further qualification) as of the date hereof and as of the Commencement Date as though made at that time.

		8.	CONDITIONS
                                         TO THE INVESTOR’S OBLIGATION TO PURCHASE SHARES OF COMMON STOCK.

The
obligation of the Investor to buy Purchase Shares under this Agreement is subject to the satisfaction or, where legally permissible,
the waiver of each of the following conditions on or prior to the Commencement Date and, once such conditions have been initially
satisfied, there shall not be any ongoing obligation to satisfy such conditions after the Commencement has occurred:

(a)               
The Company shall have executed each of the Transaction
Documents and delivered the same to the Investor;

(b)               
The Investor shall have received the opinions
and the negative assurances letter of the Company’s legal counsel dated as of the Commencement Date substantially in the
form agreed to prior to the date of this Agreement by the Company’s legal counsel and the Investor’s legal counsel;

(c)               
The representations and warranties of the Company
shall be true and correct in all material respects (except to the extent that any of such representations and warranties is already
qualified as to materiality in Section 4 above, in which case, such representations and warranties shall be true and correct
without further qualification) as of the date when made and as of the Commencement Date as though made at that time (except for
representations and warranties that speak as of a specific date, which shall be true and correct as of such date) and the Company
shall have performed, satisfied and complied with the covenants, agreements and conditions required by the Transaction Documents
to be performed, satisfied or complied with by the Company at or prior to the Commencement Date. The Investor shall have received
a certificate, executed by the Executive Vice-Chair of the Company, dated as of the Commencement Date, to the foregoing effect
in the form attached hereto as Exhibit A;

(d)               
The Board of Directors of the Company shall have
adopted resolutions substantially in the form attached hereto as Exhibit B which shall be in full force and effect
without any amendment or supplement thereto as of the Commencement Date;

    	 	21	 

     

    

(e)               
As of the Commencement Date, the Company shall
have reserved out of its authorized and unissued Common Stock solely for the purpose of effecting purchases of Purchase Shares
hereunder, 5,000,000 shares of Common Stock;

(f)                
The Irrevocable Transfer Agent Instructions shall
have been delivered to and acknowledged in writing by the Company and the Company’s Transfer Agent (or any successor transfer
agent), and the Commitment Shares required to be issued on the date of this Agreement in accordance with Section 5(f) hereof
shall have been issued directly to the Investor electronically as DWAC Shares;

(g)               
The Company shall have delivered to the Investor
a certified copy of the Certificate of Incorporation and a certificate evidencing the incorporation and good standing of the Company
in the State of Delaware, each issued by the Secretary of State of the State of Delaware, as well as a certificate evidencing
the authorization to do business in each state where the Company is required to be authorized to do business, as of a date within
ten (10) Business Days of the Commencement Date;

(h)               
The Company shall have delivered to the Investor
a secretary’s certificate executed by the Secretary of the Company, dated as of the Commencement Date, in the form attached
hereto as Exhibit C;

(i)                
The Registration Statement shall continue to
be effective and no stop order with respect to the Registration Statement shall be pending or threatened by the SEC. The Company
shall have a maximum dollar amount of Common Stock registered under the Registration Statement which is sufficient to issue to
the Investor not less than (i) the full Available Amount worth of Purchase Shares plus (ii) all of the Commitment Shares. The
Current Report and the Initial Prospectus Supplement each shall have been filed with the SEC, as required pursuant to Section
5(b), and in compliance with the Registration Rights Agreement. The Prospectus shall be current and available for issuances
and sales of all of the Securities by the Company to the Investor and for the resale of all of the Securities by the Investor.
Any other Prospectus Supplements required to have been filed by the Company with the SEC under the Securities Act at or prior
to the Commencement Date shall have been filed with the SEC within the applicable time periods prescribed for such filings under
the Securities Act. All reports, schedules, registrations, forms, statements, information and other documents required to have
been filed by the Company with the SEC at or prior to the Commencement Date pursuant to the reporting requirements of the Exchange
Act shall have been filed with the SEC within the applicable time periods prescribed for such filings under the Exchange Act;

(j)                
No Event of Default (as defined below) has occurred,
and no event which, after notice and/or lapse of time, would reasonably be expected to become an Event of Default has occurred;

(k)               
All federal, state and local governmental laws,
rules and regulations applicable to the transactions contemplated by the Transaction Documents and necessary for the execution,
delivery and performance of the Transaction Documents and the consummation of the transactions contemplated thereby in accordance
with the terms thereof shall have been complied with, and all consents, authorizations and orders of, and all filings and registrations
with, all federal, state and local courts or governmental agencies and all federal, state and local regulatory or self-regulatory
agencies necessary for the execution, delivery and performance of the Transaction Documents and the consummation of the transactions
contemplated thereby in accordance with the terms thereof shall have been obtained or made, including, without limitation, in
each case those required under the Securities Act, the Exchange Act, applicable state securities or “Blue Sky” laws
or applicable rules and regulations of the Principal Market, or otherwise required by the SEC, the Principal Market or any state
securities regulators;

    	 	22	 

     

    

(l)                
No statute, regulation, order, decree, writ,
ruling or injunction shall have been enacted, entered, promulgated, threatened or endorsed by any federal, state, local or foreign
court or governmental authority of competent jurisdiction which prohibits the consummation of or which would materially modify
or delay any of the transactions contemplated by the Transaction Documents; and

(m)             
No action, suit or proceeding before any federal,
state, local or foreign arbitrator or any court or governmental authority of competent jurisdiction shall have been commenced
or threatened, and no inquiry or investigation by any federal, state, local or foreign governmental authority of competent jurisdiction
shall have been commenced or threatened, against the Company, or any of the officers, directors or affiliates of the Company,
seeking to restrain, prevent or change the transactions contemplated by the Transaction Documents, or seeking material damages
in connection with such transactions.

		9.	INDEMNIFICATION.

In
consideration of the Investor’s execution and delivery of the Transaction Documents and acquiring the Securities hereunder
and in addition to all of the Company’s other obligations under the Transaction Documents, the Company shall defend, protect,
indemnify and hold harmless the Investor and all of its affiliates, stockholders, officers, directors, members, managers, employees
and direct or indirect investors and any of the foregoing Person’s agents or other representatives (including, without limitation,
those retained in connection with the transactions contemplated by this Agreement) (collectively, the “Indemnitees”)
from and against any and all actions, causes of action, suits, claims, losses, costs, penalties, fees, liabilities and damages,
and expenses in connection therewith (irrespective of whether any such Indemnitee is a party to the action for which indemnification
hereunder is sought), and including reasonable attorneys' fees and disbursements (the “Indemnified Liabilities”),
incurred by any Indemnitee as a result of, or arising out of or relating to: (a) any misrepresentation or breach of any representation
or warranty made by the Company in the Transaction Documents or any other certificate, instrument or document contemplated hereby
or thereby, (b) any breach of any covenant, agreement or obligation of the Company contained in the Transaction Documents or any
other certificate, instrument or document contemplated hereby or thereby or (c) any cause of action, suit or claim brought or
made against such Indemnitee and arising out of or resulting from the execution, delivery, performance or enforcement of the Transaction
Documents or any other certificate, instrument or document contemplated hereby or thereby other than, in the case of clause
(c), with respect to Indemnified Liabilities which directly and primarily result from the fraud, gross negligence or willful
misconduct of an Indemnitee. The indemnity in this Section 9 shall not apply to amounts paid in settlement of any claim
if such settlement is effected without the prior written consent of the Company, which consent shall not be unreasonably withheld,
conditioned or delayed. To the extent that the foregoing undertaking by the Company may be unenforceable for any reason, the Company
shall make the maximum contribution to the payment and satisfaction of each of the Indemnified Liabilities which is permissible
under applicable law. Payment under this indemnification shall be made within thirty (30) days from the date the Indemnitee makes
written request for it. A certificate containing reasonable detail as to the amount of such indemnification submitted to the Company
by the Indemnitee shall be conclusive evidence, absent manifest error, of the amount due from the Company to the Indemnitee, provided
that the Indemnitee shall undertake to repay any amounts paid to it hereunder if it is ultimately determined, by a final and non-appealable
order of a court of competent jurisdiction, that the Indemnitee is not entitled to be indemnified against such Indemnified Liabilities
by the Company pursuant to this Agreement. If any action shall be brought against any Indemnitee in respect of which indemnity
may be sought pursuant to this Agreement, such Indemnitee shall promptly notify the Company in writing, and the Company shall
have the right to assume the defense thereof with counsel of its own choosing reasonably acceptable to the Indemnitee. Any Indemnitee
shall have the right to employ separate counsel in any such action and participate in the defense thereof, but the fees and expenses
of such counsel shall be at the expense of such Indemnitee, except to the extent that (i) the employment thereof has been
specifically authorized by the Company in writing, (ii) the Company has failed after a reasonable period of time to assume
such defense and to employ counsel or (iii) in such action there is, in the reasonable opinion of such separate counsel,
a material conflict on any material issue between the position of the Company and the position of such Indemnitee, in which case
the Company shall be responsible for the reasonable fees and expenses of no more than one such separate counsel.

 

    	 	23	 

     

    

 

		10.	EVENTS
                                         OF DEFAULT.

An
“Event of Default” shall be deemed to have occurred at any time as any of the following events occurs:

(a)               
the effectiveness of the Registration Statement
registering the Securities lapses for any reason (including, without limitation, the issuance of a stop order or similar order),
the Registration Statement or any Prospectus is unavailable for the sale by the Company to the Investor (or the resale by the
Investor) of any or all of the Securities to be issued to the Investor under the Transaction Documents (including, without limitation,
as a result of any failure of the Company to satisfy all of the requirements for the use of a registration statement on Form S-3
pursuant to the Securities Act for the offering and sale of the Securities contemplated by this Agreement), and any such lapse
or unavailability continues for a period of ten (10) consecutive Business Days or for more than an aggregate of thirty (30) Business
Days in any 365-day period, but excluding a lapse or unavailability where (i) the Company terminates the Registration Statement
after the Investor has confirmed in writing that all of the Securities covered thereby have been resold or (ii) the Company supersedes
the Registration Statement with a New Registration Statement (as defined in the Registration Rights Agreement), including (without
limitation) when the Registration Statement is effectively replaced with a New Registration Statement covering Securities (provided
in the case of this clause (ii) that all of the Securities covered by the superseded (or terminated) registration statement that
have not theretofore been sold to the Investor are included in the superseding (or new) registration statement);

(b)               
the suspension of the Common Stock from trading
on the Principal Market for a period of one (1) Business Day, provided that the Company may not direct the Investor to purchase
any shares of Common Stock during any such suspension;

(c)               
the delisting of the Common Stock from The NASDAQ
Capital Market; provided, however, that the Common Stock is not immediately thereafter trading on T The NASDAQ Global Market,
The NASDAQ Global Select Market, the New York Stock Exchange, the NYSE Arca, the NYSE American, the OTC Bulletin Board, or the
OTCQB or the OTCQX operated by the OTC Markets Group, Inc. (or any nationally recognized successor to any of the foregoing);

(d)               
the failure for any reason by the Transfer Agent
to issue Purchase Shares to the Investor within three (3) Business Days after the applicable Purchase Date or Accelerated Purchase
Date (as applicable) on which the Investor is entitled to receive such Purchase Shares;

(e)               
the Company breaches any representation, warranty,
covenant or other term or condition under any Transaction Document if such breach could have a Material Adverse Effect and except,
in the case of a breach of a covenant which is reasonably curable, only if such breach continues for a period of at least five
(5) Business Days;

(f)                
if any Person commences a proceeding against
the Company pursuant to or within the meaning of any Bankruptcy Law;

(g)               
if the Company is at any time insolvent, or,
pursuant to or within the meaning of any Bankruptcy Law, (i) commences a voluntary case, (ii) consents to the entry of an order
for relief against it in an involuntary case, (iii) consents to the appointment of a receiver, trustee, assignee, liquidator or
similar official under any Bankruptcy Law (a “Custodian”) of it or for all or substantially all of its property,
or (iv) makes a general assignment for the benefit of its creditors or is generally unable to pay its debts as the same become
due;

    	 	24	 

     

    

(h)               
a court of competent jurisdiction enters an order
or decree under any Bankruptcy Law that (i) is for relief against the Company in an involuntary case, (ii) appoints a Custodian
of the Company or for all or substantially all of its property, or (iii) orders the liquidation of the Company or any Subsidiary;

(i)                
if at any time the Company is not eligible to
transfer its Common Stock electronically as DWAC Shares; or

(j)                
if at any time after the Commencement Date, the
Exchange Cap is reached (to the extent the Exchange Cap is applicable pursuant to Section 2(e) hereof).

In
addition to any other rights and remedies under applicable law and this Agreement, so long as an Event of Default has occurred
and is continuing, or if any event that, after notice and/or lapse of time, would reasonably be expected to become an Event of
Default, has occurred and is continuing, the Company shall not deliver to the Investor any Purchase Notice, and the Investor shall
not purchase any shares of Common Stock under this Agreement.

		11.	TERMINATION

This
Agreement may be terminated only as follows:

(a)               
If pursuant to or within the meaning of any Bankruptcy
Law, the Company commences a voluntary case or any Person commences a proceeding against the Company, a Custodian is appointed
for the Company or for all or substantially all of its property, or the Company makes a general assignment for the benefit of
its creditors (any of which would be an Event of Default as described in Sections 10(f), 10(g) and 10(h)
hereof), this Agreement shall automatically terminate without any liability or payment to the Company (except as set forth below)
without further action or notice by any Person.

(b)               
In the event that the Commencement shall not
have occurred on or before September 30, 2020, due to the failure to satisfy the conditions set forth in Sections 7 and
8 above with respect to the Commencement, either the Company or the Investor shall have the option to terminate this Agreement
at the close of business on such date or thereafter without liability of any party to any other party (except as set forth below);
provided, however, that the right to terminate this Agreement under this Section 11(b) shall not be available to
any party if such party is then in breach of any covenant or agreement contained in this Agreement or any representation or warranty
of such party contained in this Agreement fails to be true and correct such that the conditions set forth in Section 7(d)
or Section 8(c), as applicable, could not then be satisfied.

(c)               
At any time after the Commencement Date, the
Company shall have the option to terminate this Agreement for any reason or for no reason by delivering notice (a “Company
Termination Notice”) to the Investor electing to terminate this Agreement without any liability whatsoever of any party
to any other party under this Agreement (except as set forth below). The Company Termination Notice shall not be effective until
one (1) Business Day after it has been received by the Investor.

(d)               
This Agreement shall automatically terminate
on the date that the Company sells and the Investor purchases the full Available Amount as provided herein, without any action
or notice on the part of any party and without any liability whatsoever of any party to any other party under this Agreement (except
as set forth below).

    	 	25	 

     

    

(e)               
If, for any reason or for no reason, the full
Available Amount has not been purchased in accordance with Section 2 of this Agreement by the Maturity Date, this Agreement
shall automatically terminate on the Maturity Date, without any action or notice on the part of any party and without any liability
whatsoever of any party to any other party under this Agreement (except as set forth below).

Except
as set forth in Sections 11(a) (in respect of an Event of Default under Sections 10(f), 10(g) and
10(h)), 11(d) and 11(e), any termination of this Agreement pursuant to this Section 11 shall be effected
by written notice from the Company to the Investor, or the Investor to the Company, as the case may be, setting forth the basis
for the termination hereof. The representations and warranties of the Company and the Investor contained in Sections 3
and 4 hereof, the indemnification provisions set forth in Section 9 hereof and the agreements and covenants set
forth in Sections 5, 6, 10, 11 and 12 shall survive the Commencement and any termination of this Agreement.
No termination of this Agreement shall (i) affect the Company’s or the Investor’s rights or obligations under (A)
this Agreement with respect to pending Regular Purchases, Accelerated Purchases, and Additional Accelerated Purchases and the
Company and the Investor shall complete their respective obligations with respect to any pending Regular Purchases, Accelerated
Purchases and Additional Accelerated Purchases under this Agreement and (B) the Registration Rights Agreement, which shall survive
any such termination in accordance with its terms, or (ii) be deemed to release the Company or the Investor from any liability
for intentional misrepresentation or willful breach of any of the Transaction Documents.

		12.	MISCELLANEOUS.

(a)               
Governing Law; Jurisdiction; Jury Trial.
The corporate laws of the State of Delaware shall govern all issues concerning the relative rights of the Company and its stockholders.
All other questions concerning the construction, validity, enforcement and interpretation of this Agreement and the other Transaction
Documents shall be governed by the internal laws of the State of Illinois, without giving effect to any choice of law or conflict
of law provision or rule (whether of the State of Illinois or any other jurisdictions) that would cause the application of the
laws of any jurisdictions other than the State of Illinois. Each party hereby irrevocably submits to the exclusive jurisdiction
of the state and federal courts sitting in the State of Illinois, County of Cook, for the adjudication of any dispute hereunder
or under the other Transaction Documents or in connection herewith or therewith, or with any transaction contemplated hereby or
discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it
is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is brought in an inconvenient
forum or that the venue of such suit, action or proceeding is improper. Each party hereby irrevocably waives personal service
of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof to such party
at the address for such notices to it under this Agreement and agrees that such service shall constitute good and sufficient service
of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any
manner permitted by law. EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE, AND AGREES NOT TO REQUEST,
A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION HEREWITH OR ARISING OUT OF THIS AGREEMENT OR ANY
TRANSACTION CONTEMPLATED HEREBY.

(b)               
Counterparts. This Agreement may be executed
in two or more identical counterparts, all of which shall be considered one and the same agreement and shall become effective
when counterparts have been signed by each party and delivered to the other party; provided that a facsimile signature or signature
delivered by e-mail in a “.pdf” format data file shall be considered due execution and shall be binding upon the signatory
thereto with the same force and effect as if the signature were an original signature.

    	 	26	 

     

    

(c)               
Headings. The headings of this Agreement
are for convenience of reference and shall not form part of, or affect the interpretation of, this Agreement.

(d)               
Severability. If any provision of this
Agreement shall be invalid or unenforceable in any jurisdiction, such invalidity or unenforceability shall not affect the validity
or enforceability of the remainder of this Agreement in that jurisdiction or the validity or enforceability of any provision of
this Agreement in any other jurisdiction.

(e)               
Entire Agreement. The Transaction Documents
supersede all other prior oral or written agreements between the Investor, the Company, their affiliates and Persons acting on
their behalf with respect to the subject matter thereof, and this Agreement, the other Transaction Documents and the instruments
referenced herein contain the entire understanding of the parties with respect to the matters covered herein and therein and,
except as specifically set forth herein or therein, neither the Company nor the Investor makes any representation, warranty, covenant
or undertaking with respect to such matters. The Company acknowledges and agrees that is has not relied on, in any manner whatsoever,
any representations or statements, written or oral, other than as expressly set forth in the Transaction Documents.

(f)                
Notices. Any notices, consents or other
communications required or permitted to be given under the terms of this Agreement must be in writing and will be deemed to have
been delivered: (i) upon receipt when delivered personally; (ii) upon receipt when sent by facsimile or email (provided confirmation
of transmission is mechanically or electronically generated and kept on file by the sending party); or (iii) one Business Day
after deposit with a nationally recognized overnight delivery service, in each case properly addressed to the party to receive
the same. The addresses for such communications shall be:

If
to the Company:

Enochian
BioSciences, Inc.

2080
Century Park East

Suite
# 906

90067
Los Angeles, CA

Telephone:
786-888-1685

E-mail:
lpuche@enochianbio.com

Attention:
Luisa Puche

With
a copy to (which shall not constitute notice or service of process):

 

K&L
Gates, LLP

200
S. Biscayne Blvd., Ste. 3900

Miami,
Florida 33131

Telephone:(305)
539-3306

Facsimile:
(305) 358-7095

E-mail:
clayton.parker@klgates.com

Attention:Clayton
E. Parker, Esq.

    	 	27	 

     

    

If
to the Investor:

Lincoln
Park Capital Fund, LLC

440
North Wells, Suite 410

Chicago,
IL 60654

Telephone:(312)
822-9300

Facsimile:(312)
822-9301

E-mail:jscheinfeld@lpcfunds.com/jcope@lpcfunds.com

Attention:Josh
Scheinfeld/Jonathan Cope

If
to the Transfer Agent:

Action
Stock Transfer

2469
E. Fort Union Blvd, Suite 214

Salt
Lake City, UT 84121

Telephone:
(801) 274-1088

Facsimile:
(801) 274-1099

Email:
jb@actionstocktransfer.com

Attention:
Justeene Blankenship

 

or
at such other address, email and/or facsimile number and/or to the attention of such other Person as the recipient party has specified
by written notice given to each other party three (3) Business Days prior to the effectiveness of such change. Written confirmation
of receipt (A) given by the recipient of such notice, consent or other communication, (B) mechanically or electronically generated
by the sender’s facsimile machine or email account containing the time, date, and recipient facsimile number or email address,
as applicable, and an image of the first page of such transmission or (C) provided by a nationally recognized overnight delivery
service, shall be rebuttable evidence of personal service, receipt by facsimile, email or receipt from a nationally recognized
overnight delivery service in accordance with clause (i), (ii) or (iii) above, respectively.

(g)               
Successors and Assigns. This Agreement
shall be binding upon and inure to the benefit of the parties and their respective successors and assigns. The Company shall not
assign this Agreement or any rights or obligations hereunder without the prior written consent of the Investor, including by merger
or consolidation. The Investor may not assign its rights or obligations under this Agreement.

(h)               
No Third Party Beneficiaries. This Agreement
is intended for the benefit of the parties hereto and their respective permitted successors and assigns, and, except as set forth
in Section 9, is not for the benefit of, nor may any provision hereof be enforced by, any other Person.

(i)                
Further Assurances. Each party shall do
and perform, or cause to be done and performed, all such further acts and things, and shall execute and deliver all such other
agreements, certificates, instruments and documents, as the other party may reasonably request in order to consummate and make
effective, as soon as reasonably possible, the Commencement, and to carry out the intent and accomplish the purposes of this Agreement
and the consummation of the transactions contemplated hereby.

(j)                
No Strict Construction. The language used
in this Agreement will be deemed to be the language chosen by the parties to express their mutual intent, and no rules of strict
construction will be applied against any party.

(k)               
Remedies, Other Obligations, Breaches
and Injunctive Relief. The Investor’s remedies provided in this Agreement, including, without limitation, the Investor’s
remedies provided in Section 9, shall be cumulative and in addition to all other remedies available to the Investor under
this Agreement, at law or in equity (including a decree of specific performance and/or other injunctive relief), no remedy of
the Investor contained herein shall be deemed a waiver of compliance with the provisions giving rise to such remedy and nothing
herein shall limit the Investor’s right to pursue actual damages for any failure by the Company to comply with the terms
of this Agreement. The Company acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the
Investor and that the remedy at law for any such breach may be inadequate. The Company therefore agrees that, in the event of
any such breach or threatened breach, the Investor shall be entitled, in addition to all other available remedies, to an injunction
restraining any breach, without the necessity of showing economic loss and without any bond or other security being required.

    	 	28	 

     

    

(l)                
Enforcement Costs. In the event of a dispute
arising out of or relating to this Agreement, if a court of competent jurisdiction determines in a final, non-appealable order
that a party has breached this Agreement, then, in addition to any other available remedies, the non-breaching party shall be
entitled to, and the breaching party shall be liable for, the reasonable legal fees and expenses incurred by the non-breaching
party in connection with the dispute, including any appeals in connection therewith. If: (i) this Agreement is placed by the Investor
in the hands of an attorney for enforcement or is enforced by the Investor through any legal proceeding; (ii) an attorney is retained
to represent the Investor in any bankruptcy, reorganization, receivership or other proceedings affecting creditors' rights and
involving a claim under this Agreement; or (iii) an attorney is retained to represent the Investor in any other proceedings whatsoever
in connection with this Agreement, then the Company shall pay to the Investor, as incurred by the Investor, all reasonable costs
and expenses including attorneys' fees incurred in connection therewith, in addition to all other amounts due hereunder.

(m)             
Waiver; Failure or Indulgence Not Waiver.
No provision of this Agreement may be waived other than in a written instrument signed by the party against whom enforcement of
such waiver is sought. No failure or delay in the exercise of any power, right or privilege hereunder shall operate as a waiver
thereof, nor shall any single or partial exercise of any such power, right or privilege preclude other or further exercise thereof
or of any other right, power or privilege.

**
Signature Page Follows **

 

    	 	29	 

     

    

 

 

IN
WITNESS WHEREOF, the Investor and the Company have caused this Purchase Agreement to be duly executed as of the date first
written above.

 

 

THE
COMPANY:

 

ENOCHIAN
BIOSCIENCES, INC.

 

By:/s/
Mark Dybul ___________

Name:
Mark Dybul

Title:
Executive Vice-Chair

 

 

INVESTOR:

 

 

LINCOLN
PARK CAPITAL FUND, LLC

BY:
LINCOLN PARK CAPITAL, LLC

BY:
Rockledge Capital Corporation

 

 

By:_/s/
Josh Scheinfeld_______

Name:
Josh Scheinfeld

Title:
President

 

 

    	 	30	 

     

    

 

 

EXHIBITS

 

Exhibit
A          Form of Officer’s Certificate

Exhibit
B           Form of Resolutions of the Board of Directors of the Company

Exhibit
C            Form of Secretary’s Certificate

 

    	 	31

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00311-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00311-of-00352.parquet"}]]